# **Biotech** finances

# www.biotech-finances.com

### **Europe**

• The issuing of bonds has been a great success this half-year ....p. 1-2

### France

• Biotech businesses have been resilient, but need a swift recovery ......p. 3

### **British Isles**

 M&A activityhas been non-existent over this half-year ......p. 4

### **Germanic countries**

• VCs desert stock markets .....p. 4

### **Switzerland**

 Record fundraising for private Swiss biotech companies despite difficult financing environment.....p. 5

### **Nordic countries**

• Opportunities for secondary transactions are increasing ......p. 6

#### **Benelux**

• Good quality enterprises have maintained their value ......p. 6

#### Italy

• Institutional investors fall back on medtech ......p. 7

#### Spain

• Businesses are forced to limit their developments......p. 7

### **Eastern Europe**

• Our economic fabric needs structure ......p. 8

#### Israel

• Medical devices companies are very sought after in Israel......p. 8

### €Deals

• Financial biotransactions in Europe and Israel in H1 2009 ......p. 9-20

### €deals Special

### THE ISSUING OF BONDS HAS BEEN A GREAT SUCCESS THIS HALF-YEAR

Biotech companies in Europe have suffered severely from the lack of financing during the first half-year of 2009. Fundraising rounds have slowed down significantly and stock market registrations have stopped. Only M&A operations are still the order of the day, allowing partly for the rationalization of research and development costs. Vivien de Coincy, Investment Analyst, Crédit Agricole Chevreux SA, gives his views on the investment climate in European biotech business at the half-way point through 2009.

### **BIOTECH FINANCES:**

Do you think the wave of consolidations experienced in pharma will cross over to biotech? What are the most essential assets currently for a pharma in order to be a good target?

Vivien de Coincy : Connections between biotechs obey different rules to those between pharmas. The former are determined by the race to achieve critical mass, to diversify their portfolio (often in one overall domain) and/or their financing (if one of the parties has a comfortable and underused amount of cash available). Consolidation between biotechs occurs in a context of increased difficulty in renewing their portfolios, while the big pharma players have a growing need for new innovative projects, whether it's to consolidate their R&D portfolios, or to acquire certain technological platforms (monoclonal antibodies, RNA interference, etc.). This strong need of innovation will probably result in the continuation of the acquisition trend of biotechs by

pharmaceutical groups in the next few months, particularly in the field of organic products (reduced risk of copying in the long term, reduced risk of failure in clinical development in the medium term), with as a result an inflation in access costs to these products. Some of these operations will also involve already partnered companies (for example Sanofi / Acambis in 2008, Bristol Myers-Squibb / Medarex in July 2009), as a result of the visibility they gained on common projects.

August 31, 2009 – No. 428

#### **BIOTECH FINANCES:**

# Will pharmas focus on acquiring specific products or on entire biotechs?

**V.D-C**: The pharmaceutical industry will operate a dual acquisition strategy, through "purchasing" product licenses, which will in some cases be followed by taking global control of the partner, and through specific acquisitions of specialized biotech companies in niche areas (for example BiPar by Sanofi-Aventis in April 2009, specialized in PARP inhibitors, a new family of anti-cancer drugs). It wouldn't make sense to acquire entire biotechs in terms of products at the risk bearing stages of development, because in case of failure the targeted biotech becomes a drain on capital requiring restructuring. The transactions in this domain should remain similar to recent schemes where the pharma and the biotech share the risk in the clinical development stages. Consequently, pharmas will prioritize the purchase of licenses, which weigh much less on their account results and their balance, with the option to pay an overall additional amount if they decide to absorb the biotech at a more advanced stage. Recent deals show that pharmas, which are still generating lots of cash, are less motivated by the financial conditions as by the exclusivity conditions of the candidate product, whether it's in terms of potential indications or geographical areas.

#### **BIOTECH FINANCES:**

What is the importance of connections such as the one between Roche and Genentech? Will this be a precedent that will be repeated in the next few years?

**V.D-C**: Deals like these aren't actually new as such, even if this one is new in terms of the size of the targeted biotech, which had reached a status that was almost equivalent to a more mature (and certainly more specialized) pharmaceutical company. Furthermore, the deal involves two entities that have known each other well since the early 1990s, as Roche has been a long term shareholder and a favored partner in research and commercial ventures (outside the United States). For this reason, this is more an operation of optimal (financial) integration than a pure and simple acquisition. We can't exclude the possibility that Amgen will

### AMGEN COULD one day become a TARGET, or a PREDATOR

one day become a target, or a predator, but the reality would resemble more a "marriage" between large pharmaceutical groups.

#### **BIOTECH FINANCES:**

Would it be unrealistic to attempt an entrance to the stock market in today's Europe? What means are available to CEOs of listed biotechs currently in need of raising funds?

V.D-C : The decision on registering on the stock exchange and its potential success depends on various criteria. The company's profile will determine its atrractiveness to investors, and the preference will go to technological platforms with the opportunity for service provision (with low-risk R&D and rapid cash flow generation for financial autonomy), or R&D profiles with a visible portfolio that is sufficiently advanced to support clinical news flow and profitable partnering. In times when markets are recovering, the return to more risky assets (which are also more attractive in terms of gaining value) tends to materialize in all areas. Biotechnology should benefit equally, as long as the business case is promising and not just in start-up or capital development phase. CEOs in biotech could prioritize the private placement formula, in case the market would still turn its back to poor liquidity in the runup to flotation and of that phase in the cycle.

#### **BIOTECH FINANCES:**

In which way is the issuing of shares particularly profitable at the moment? Do you think that a recovery of the economy could open an IPO window by the end of the year?

V.D-C : The issuing of shares has been very successful, especially for those offering an activity profile with a long cycle that generates cash (pharma, utilities). Returns have been higher than the state share issues of an equivalent maturity (such as for example the OATs, the French government bonds), while remaining well under the implicit capital cost resulting from poor value creation on the stock market. Large insurance companies have been the big investors in this area (low risk and attractive return). The issuing of debts, often convertible, has been more common in the United States than in Europe in the biotech sector. In Europe there is a much larger pool of specialized investors. The prospect of a new window of opportunity on the stock market for biotech by the end of 2009 remains very uncertain, especially in the largest European markets where stock markets have barely risen since the end of 2008 and where investors are only moving back very slowly to sectors with a more risky cycle. In the current phase, they're still targeting their support at recipients with good liquidity, in order to operate a trade-off as quickly as possible.

> Interview taken by Juliette Lemaignen

### Pact&Partners International

A HUMAN RESOURCE GROUP SPECIALISING IN EXECUTIVE RECRUITING, HR CONSULTING Contact Olivier Safir

Pact & Partners International - 12, rue du Faubourg Saint Honoré - Paris 75008 - France T: 33 (0)1 53 43 83 00 - F: 33 (0)1 42 66 12 01





Jean-Yves Nothias, General Partner BioConvergence Team Société Générale Asset Management Private Equity capital access for investors. Clearly, this situation generates capital investment opportunities, which remain the favored source of funding for biotech companies. The capital risk industry turns out to be one of the strongest links in the recovery of high technology businesses.

Still, the sector feels a lack of support.

A SWIFT RECOVERY

**BIOTECH BUSINESSES HAVE** 


**BEEN RESILIENT, BUT NEED** 

Capital risk financing seems to have hit rock bottom between mid-2008 and mid-2009 worldwide. Biotechs haven't been immune to this overwhelming dive. Investment has fallen to levels last seen before 1999. Due to the lack of capital raised on the stock markets over the last year and more, capital risk investors can't exit from their stakes and their funds are ageing. As a result, their funds' profitability is reduced, new capital raising is slowed down and the injection of new capital into enterprises is inhibited. However, there is a whole generation of companies that need to supplement their capital in order to reach the required objectives on exit of their initial investments. Will the situation improve by 2010? Are we about to see the emergence of a new model for the capital risk industry?

The lack of appetite of investors for biotech companies is mainly due to the reluctance to take a risk, which is exacerbated by the worldwide financial crisis. These factors have caused a general reduction in value building, and a toughening of loan conditions or Some blame the financial institutions for turning their backs on capital risk. Others blame the scattering or misuse of financial tools such as tax incentives by the state, which offers a growing number of solutions. In this gloomy situation, we have to count ourselves lucky for the record amounts provided by OSEO, the French agency that provides assistance and financial support to SMEs, notably through the ISI program for strategic industrial innovation. And finally, most deplore the general lack of performance of investment teams. Everyone points their finger elsewhere. Where is the biotechnology industry in all of this? Those with sufficient capital have survived better than those in other sectors. But if they can't renew their funding, they will have only one option: sell to the highest bidder.

The large industrial companies have also seized the opportunity. Megaacquisitions are continuing to change the industrial pharmaceutical landscape, which is slowly changing into a BIOpharmaceutical industry. Acquisitions of medium-sized businesses are continuing in all sectors and all phases, but at fiercely negotiated prices, where sellers are hard to please. The worry is that in the case of a fall in prices, those businesses that have been unable to control their capital levels and find sufficient financial support to replenish their coffers, will find themselves in difficulty.

On the other hand, quality projects should find themselves in a strong position and this promises some very nice deals. But whatever happens, health remains a growing sector, and clinical data are still the most tangible asset to attract the interest of the industrialists. Biotech companies are at the heart of economic recovery in the United States. They follow a strong trend towards the new paradigm of personalized medicine. After a very quiet H2 2008, we were expecting the worst for 2009. Some were forecasting a nuclear winter, others the crossing of the valley of death. None of this came to pass. The main thing has been to survive, and the levels of capital assets seemed to be the only indicators of value in the eyes of the confused analysts. The profound changes of 2008 - 2009, in economic and political terms, offer opportunities of growth, notably who develop for companies technologies where IT, biochemistry and micro-mechanics converge. Only by standing back can you start considering the future calmly.



As many of you are aware, since January 2009 the weekly newsletter Biotech Finances has been **PUBLISHED IN ENGLISH**. We continue to build on our 10 years' experience as the leading French publication in the sector as we reach out to a much larger readership, increasing our exposure significantly. In just a few weeks, the percentage of unique visitors to our website from the US has increased six-fold!

**BY SUBSCRIBING TO BIOTECH FINANCES**, you will receive independent, pertinent, and high quality information on your preferred sector, **AND ALSO** you will become part of our mission to give biotech companies far and wide inspiration and improved performance.





### BIOTECH M&A ACTIVITY HAS BEEN NON-EXISTENT OVER THIS HALF-YEAR

investor MVM, will take the company to 2012 with an internal pipeline of small molecules against GPCRs.

Ireland followed in pursuit with another high profile fundraising at Opsona Therapeutics in May, led by Novartis Venture Fund. Opsona raised its Series B financing at 18 M€ to continue developing biopharmaceutical and small molecule products which modulate the innate immune system through targeting toll like receptor pathways. The trend of increasing activity from corporate VCs, already seen in the US and rest of Europe, was also evident in the UK and Ireland, with Roche and Novartis Venture funds joining this round.

Chroma Therapeutics, a later-stage UK biotech, raised a £15M (17 M€) series D in June from their current investors, with a contribution from GSK, which at the same time announced a collaboration deal on macrophage targeted drugs. Chroma is in PhII with a small molecule drug for AML and is also pushing

forward a macrophage targeted HDAC inhibitor in PhI.

Interest was not purely on the cancer and inflammation companies however and Novacta Biosystems of UK raised \$21M (14.5 M€) from Celtic Pharma to bring to clinic their lantibiotics platform of anti-infectives for hospital infections. Straightforward M&A activity in the biotech sector was non-existent in these two markets and no IPOs were even rumoured. Some follow-on public offerings took place in a drip feed fashion.

The investor outlook is however improving and should appear more colorful in the next year if not the second half of 2009.

The IPO of Cumberland on Nasdaq broke a nearly two-year drought for IPOs in the pharmaceutical sector and has brought more hope to the market that should follow to this side of the Atlantic in the next two/three quarters".



Hakan Goker, *Analyst* Atlas Venture

"The first half of 2009 eventually gave the UK and Irish biotech its first slight sigh of relief since the dark end of last year. Although few in number, UK and Irish private biotech managed to attract high profile investors and formidable amounts of funding in a largely inactive market.

One of largest sums raised, at £21M (24 M€), was achieved by Heptares, based in the UK, developing a novel GPCR platform to enable accessing these famously difficult, albeit abundant, therapeutic targets. The £21M raise was led by Clarus, who were joined by Novartis Venture Fund and existing



### **VCs DESERT STOCK MARKETS**

GERMANIC COUNTRIES



The significant wave of acquisitions, which was characteristic for the German-speaking countries (Germany, Austria and Switzerland) this time last

Hanns-Peter

The Global

Life Science

Ventures

GmbH

Wiese, Partner year, wasn't sustained this half-year. Nevertheless, there have been a dozen small acquisitions by pharmas, medtechs and even biotechs. The latter have however not been a clear success for the sellers, who have only achieved weak value creation. Capital risk, even though it's independent from bank financing, continues to suffer from the financial crisis. The window for IPOs remains shut. and compared to the same period last year, the number of transactions in Germany has gone down by approximately half, with government institutions most affected, in spite of the fact that VCs are deserting the stock markets. Latent value has continued to decline, as well as the return on exits from positions that have commonly been acquired at very low introduction prices. As to private finance, the Austrian company Protafin has been one of the only biotechs to have raised significant funds, with a 14 M€round from a group of VCs from the United States and the Benelux.



Ulrich Geilinger, *Board Member* HBM Partners – Zug

### PUBLIC STOCK PERFORMANCE & IPOS

During the first half of 2009, the majority of Swiss biotech public stocks continued to decline (average performance -6%) after an already disappointing performance during 2008. Only Newron showed a strong performance (+95.3%). Arpida also gained 15% after its stock dropped to below €0.66 in 2008 after the failure of their lead product. Actelion again outperformed the market (-3.4%). Basilea (-36.7%), Cytos (-48.2%) and Santhera (-30.4%) saw their share prices drop after the announcement of negative clinical or regulatory news. Since the beginning of 2008, Swiss biotech stocks on average dropped by more than 50%. As expected, no IPOs were reported during the period. And most experts consider it unlikely that the IPO window will open up anytime soon for biotech stocks.

#### **PRIVATE FINANCING**

Despite the difficult financing environment, the private biotech financing market in Switzerland was surprisingly active with a record sum of CHF 195 million (125 M€) raised by eight companies. The financing amount during H1 09 was thus higher than the

### RECORD FUNDRAISING FOR PRIVATE SWISS BIOTECH COMPANIES DESPITE DIFFICULT FINANCING ENVIRONMENT

amount raised during the whole of 2008 (120 M€). Four companies reported financings of over 10 M€ Novimmune, the immunology-focused antibody company, raised CHF 62 million (41 M€. The financing was led by Swiss BZ Bank. AC Immune, developing new Alzheimer drugs, received CHF 40 million (26 M€) from existing investors. The third largest amount (CHF 32 million, 21 M€) was raised by Baslebased Synosia, a company with a clinical pipeline in psychiatry and neurology. The financing was led by new investors Aravis Venture and Investor Growth. GlycoVaxyn, a developer of conjugated vaccines, also was able to raise CHF 25 million (17 M€) in a round led by Edmond de Rothschild.

Smaller amounts were raised by Kenta Biotech from existing investors (CHF 12 million, 8 M€, developing antibacterial antibodies, and CT Atlantic (CHF 10 million, 6.5 M€, a new company developing anti-cancer antibodies. The financing of CT Atlantic was led by HS Life Sciences, a new Swiss life sciences venture fund initiated by experienced biotech investor/entrepreneur Karsten Henco. Also during H1 09, Anteis received CHF 7 million (4.5 M€) of expansion capital to start the marketing of its aesthetic dermatology products in the US. Finally, Lumavita topped up its Series A round from 2008 with an additional CHF 6 million (4 M€) to launch its Femifect vaginitis product.

#### **VENTURE FUNDS**

At the beginning of 2009, HS LifeSciences AG of Zurich launched a new investment fund, QureInvest AG, dedicated to new start-up biotech companies, with an initial CHF 27.5 million (18.7 M $\oplus$ ) from an international group of private investors. In March 2009, Merck Serono announced the launch of their corporate venture capital fund, Merck Serono Ventures, with an initial commitment to invest up to 40 M $\in$  At the end of June 2009, BB Biotech Ventures reported the closing of their third fund with a committed capital of \$100 million (67.5 M $\oplus$ .

#### **MERGERS AND ACQUISITIONS**

No Swiss biotech (or pharma company) was acquired during the first half of 2009. The major news in the Swiss pharma/biotech sector during that period was of course the full acquisition of Genentech by Roche. This transaction was completed in March 2009.

### CONCLUSIONS

The record fund raising during the first half of 2009 in Switzerland again demonstrated the strong position of Switzerland in the European biotech industry. With the IPO window being closed, access to private capital is crucial for the survival of many biotech companies.

While licensing and M&A activity in the biotech/pharma sector continues to be reasonably strong, no Swiss biotech company during H1 09 was able to exit by trade sale. With many companies and products up for sale, it has become increasingly difficult to attract the attention of potential buyers. However, we expect a pick up in M&A activity in Switzerland also as companies progress their product pipelines and seek an exit for investors".

### www.biotech-finances.com

Leader in business information for bio-deciders and bio-investors. More than 400,000 stakeholders from the life sciences sector around the world connect every year. **OPPORTUNITIES FOR SECONDARY** 

TRANSACTIONS ARE INCREASING



NORDIC COUNTRIES



Eric Leire, Partner BioFund Venture

On the subject of

private financing, the landscape is

varied. There have been several funding

round closures in Scandinavian business

by local companies. For example, Sunstone Capital is one of the remaining

active funds, for follow-on as well as for

seed funding. At the same time, various biotechnology companies have had to close or to yield their intellectual property due to a lack of sufficient funds to continue their activity. This was for example the case with NatImmune A/S, who had to sell its shares to the Danish company IPC Pharma. M&A operations have been numerous this half-year, with great returns for investors. Overall, we have seen fewer mergers than collaboration deals involving the main players in pharma. For example Santaris has signed a global alliance with GlaxoSmithKline on the identification and the development of new candidate

drugs. On the stock market nothing significant has happened over the past half-year. The IPO window is firmly shut and isn't expected to open for one or two years. Until then, the contenders are sitting tight, ready to bounce back as soon as it becomes possible. Consequently, VCs save their money for supporting existing lines, while strictly limiting new dossiers. However, we have raised funds through BioFund to carry out secondary transactions for purchasing venture assets. There are many opportunities of that nature currently and it's possible to get investors together for that. 



#### BENELUX



Pieter van der Meer, Investment Director Gilde

Stock market registered biotech businesses in the Benelux have gone through a remarkable phase of recovery during the first half-year of 2009. Almost all stocks are growing significantly, and most have outperformed other stocks. Some companies have even seen their

stocks rise by 70 to 100%, demonstrating the attraction and maturity of this relatively new market. Amongst the success stories are Ablynx (+27%), AMT (+27%), Crucell (+58%), Thrombogenics (+69%), Galapagos (+84%), Devgen (+95%) and Tigenix (109%).

MAINTAINED THEIR VALUE

**GOOD QUALITY ENTERPRISES HAVE** 

The Benelux has also maintained its attraction for private investors. Dutch actors have extended their capital base in recent years by working together with government funds. The crucial activity of these new actors is now starting to become visible. In spite of the unfavorable economic climate, the number of start-ups has continued rising

this half-year, and some already established actors have succeeded in attracting new investments from abroad for their follow-on. Even the acquisition prices have improved. Consequently, good quality companies should maintain their value. As far as the current halfyear is concerned, we're expecting the completion of some private placements, mainly in The Netherlands. Companies such as Agendia are in advanced stages with their funding rounds and their closures should be announced in the next few months. Stock market registrations are not yet the order of the day. However, several biotech companies are ready to go ahead as soon as the markets turn around. 



### INSTITUTIONAL INVESTORS FALL BACK ON MEDTECH



Simone Zanolo, *General Manager* Filarete Investimenti S.p.a.

The last half-year has been very quiet in terms of financing operations in biotech companies in Italy. Financiers are cautious and businesses are not really doing anything exciting. We've also had some major failures this half-year: BioXell (SIX : BXLN), which had raised more than 50 M€ and had products in clinical trials, has become the first victim, with the failure of its lead product in phase III. This was a real blow for the management, which has changed its CEO and launched a restructuring process and a shift in focus а new pipeline. Newron to Pharmaceuticals, another prominent Italian biotech company, has also had scientific problems in phase III of the Safinamide molecule. These two failures have diminished a little further the already weakened confidence of institutional investors, who are more and more taking refuge in medtech, which is similar to biotech but much lower in risk and in cash consumption. In terms of raising funds the situation is particularly difficult at the moment, both for businesses and for financing vehicles

such as our seed fund, which we are struggling to close. This lack of funds will result in the closure of several companies in the next few months. There are already two obvious examples: the closure of the Italian research center Cell Therapeutics, which should be imminent, as well as the end of research activities of Nerviano Medical Sciences, a Farmacia spin-off, which hasn't achieved the commercial results it anticipated for its lead product. The one small positive note this halfyear has been the series A of 8.2 M $\in$ closed by Ethical Oncology Science (EOS) with Sofinnova Ventures and Quantica SGR last March.



### BUSINESSES ARE FORCED TO LIMIT THEIR DEVELOPMENTS



Joël Jean-Mairet, *Co-founding Partner* Ysios Capital Partners

The first half-year of 2009 has been very quiet for the biotechnology sector, with practically no financing activity. Only a few small seed transactions have been made by specialized local funds. VCs have generally been sitting tight, saving their funds for their existing lines. This was the case for Ysios Capital Partners, who are planning a reinvestment in Cellerix through a large financing round due in fall 2009. There are other funding projects in the pipeline, but they aren't due to complete until 2010 or even 2011. In terms of businesses, the lack of financing is clearly beginning to make itself felt, even though we haven't seen any companies being forced to cease their activity, as has been the case in other countries. The adopted strategy in this situation consists of limiting projects, and to focus on products that have a potential of a return on investment in the short term. No IPOs have taken place, in spite of the implementation of Spain's new small-cap exchange, the Mercado Alternativo Bursátil (MAB), in March 2008, which is dedicated to supporting SMEs entering the stock markets. The outlook for a return to normal is still uncertain, and is not predicted until 2010 at the earliest.



EASTERN EUROPE



Nevenka Kregar Velikonja, *Managing Director* Educell

The biotechnology landscape of Eastern Europe is still very sparse. For example in

### OUR ECONOMIC FABRIC NEEDS STRUCTURE

Slovenia we have between ten and twenty more or less mature SMEs, which is very few, especially as they're not organized in terms of either location or networking. The government has tried to implement networking programs, but in practice it has hardly been used and the only truly effective collaborations are those between universities, research institutes and private businesses. Financing specialists can be counted on the fingers of one hand, but the regional incentives are relatively significant so we don't seem too badly affected by the economic crisis. In our case, we still have around one year's worth of cash available, which leaves us time to envisage other financing solutions. By then, the basic local structures should have been established, and we should be able to attract investors from all over Europe and even the United States.



### MEDICAL DEVICES COMPANIES ARE VERY SOUGHT AFTER IN ISRAEL



Efrat Zakai, *Director of Research* Israel Venture Capital Research Center

During the first quarter of 2009, twentyfive life sciences companies raised 35  $M \in 19\%$  of the total capital raised, compared with 102.6  $M \in$ or 24% in the first quarter of 2008, and 45.4  $M \in$ or 17% in the previous quarter. Within the life sciences sector, the medical devices subsector attracted 19.6 M $\in$  56% of the amount raised in the entire sector, and 11% of total capital raised by all sectors.

In the second quarter of 2009, the life sciences sector led capital raising with 27% of total capital raised, followed by software with 23%, and internet with 14%. The communications and the life sciences sectors led capital raising in H1 2009, each with 23% of capital raised, followed by software with 22% and

internet with 12%. The life sciences sector led capital raising in the second quarter with 35 companies attracting 53 M€ - 27% of capital raised. This compares with 28.6 M€or 9% raised in the second quarter of 2008. Within the life sciences sector, the medical devices subsector attracted 40.5 M€ 73% of the amount raised in the entire sector, and 21% of total capital raised by all sectors. In H1 2009, life sciences led all sectors, raising 88 M€ or 23% of the total capital raised.

PREMIUM SUBSCRIPTION

**PLEASE RETURN TO BIOTECH FINANCES EEI -** Fax. + 33 9 8008 5146 / Mail. subscriptions@biotech-finances.com I would like to subscribe to the Biotech Finances Newsletter for one year, including: 44 issues + the Biomap + access to our web services and the Newsletter Smartphone (current newsletter + archives + international on-line news articles, the on-line Biomap, etc.), the complete archives starting from 1999 (in English from Issue 401, January 2009). **1 YEAR : 1170,00**  $\in$ 

Payment by bank transfer: Ad	ccount name: EDITIONS	EUROPEENNES DE	L'INNOVATION
------------------------------	-----------------------	----------------	--------------

RIB / Bank code: 10468 / Branch code: 02283 / Account No. 20705100200 / RIB Key: 57 / Home town: LYON LAFAYETTE / IBAN: FR76 1046 8022 8320 7051 0020 057 / BIC: SWIFT BIC: RALPFR2G

### **Payment by bank card: Visa and Mastercard only**

Expiry date : / 20 Security code : N°	
Please fill in your details below, or include your business card.	
First name :	.Surname :
Company :	.Profession :
Adress :	.Postcode and town :
Country :	.Email :
Phone. :	
Fax. :	5

			FINANCIAL BIO	TRA	NSACTIO	NS IN FRANCE FOR H	1 2009				
	Acquiror name	Acquiror country code	Target name	Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR
1	AGF Private Equity SA Emertec Gestion SA CEA Investissement	FR FR FR	Alchimer SA	FR	7 216,35	Minority stake unknown %	Completed	Development capital - 4th round Private Equity	Cash	n.a.	n.a.
2	Auriga Partners SA NBGI Private Equity Ltd Bioam Gestion SA Edmond de Rothschild Investment Partners SAS Crédit Agricole Private Equity SA Wellington Partners GmbH ICSO Private Equity	FR GB FR	SuperSonic Imagine	FR	26000,00	Minority stake unknown %	Completed	Development capital - 2nd round Venture capital	Cash	n.a.	n.a.
3 4	Axygen Bioscience Inc. Banque de Vizille	US FR FR FR FR	Articles de Laboratoire de Précision SA ImmunID SAS	FR FR	n.a. 2400,00	Acquisition unknown majority stake % Minority stake unknown %	Completed Completed	Venture capital Development capital	Cash	n.a. n.a.	n.a. n.a.
5	Bavaria Industriekapital AG	DE	Catalent Pharma Solutions Inc's oral	FR	n.a.	Institutional buy-out 100%	Completed	Private Equity		n.a.	n.a.
6	Caisse des Dépôts et Consignations Ouest Ventures Naxicap Partners SA Terrena Fonds d'Investissement de Bretagne	FR FR FR FR FR	manufacturing business Agrauxine SAS	FR	4600,00	Minority stake unknown %	Completed	Private Equity Corporate venturing Development capital	Cash	n.a.	n.a.
7	Hanalei Finance Cap Décisif SAS G1J-Ile-de-France	FR FR FR	InnaVirVax SAS	FR	1100,00	Minority stake unknown %	Completed	Development capital - 1st round Venture capital	Cash	n.a.	n.a.
8	Daiichi Sankyo Co., Ltd	JP	Merck Lipha Santé SAS' primary care sales activities	FR	n.a.	Acquisition 100%	Completed	venture capitar		n.a.	n.a.
9 10	Siparex Ingenierie et Finance Sofinnova Partners Vertex Venture Holdings Ltd Granite Global Ventures QUALCOMM Ventures Nokia Growth Partners LP EuroUs Ventures	FR BE FR SG US US US US	Sales activities Nymphea Environnement SA Inside Contactless SA	FR FR	n.a. 31700,00	Minority stake unknown % Minority stake unknown %	Completed Completed	Development capital - 3rd round Private Equity Corporate venturing	Cash	n.a. n.a.	n.a. n.a.
11	Visa International Service Association Grand Delta Angels	US FR	Eco2 Distrib SAS	FR	n.a.	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
12	HealthpointCapital LLC	US	Scient'X SA	FR	n.a.	Minority stake unknown %	Completed	Angel Investment Development capital Private Equity	Cash	n.a.	n.a.
13	Inserm-Transfert Finistere Partners LLC	FR US	Hemarina SA	FR	1,000.00 *	Minority stake unknown %	Completed	Development capital - 1st round Venture capital	Cash	n.a.	n.a.
	Johnson & Johnson Laboratoire Pasteur Cerba	US FR	Vania Expansion SNC Biolille Selarl	FR FR	n.a. n.a.	Acquisition 100% Minority stake unknown %	Announced Completed	New bank facilities		n.a. n.a.	n.a. n.a.
16	Laboratoire Unither SAS	FR	Sanofi-Aventis SA's factory in Colomiers Groupement Domagri Maicentre	FR	na	Acquisition 100%	Rumour	Private Equity		n.a.	n.a.
18	Limagrain SCA Minakem SAS	FR FR	AstraZeneca Dunkergue Production	FR	n.a. n.a.	Acquisition 100% Acquisition 100%	Announced Completed			n.a. n.a.	n.a. n.a.
19 20	Ogilvy Healthworld SAS Oséo	FR FR	LOb Conseils SA Cerenis Therapeutics SA	FR FR	n.a. 2500,00	Acquisition unknown majority stake % Minority stake unknown %	Completed Completed	Development capital	Cash	n.a. n.a.	n.a. n.a.
21	Oséo Innovation SA	FR	TCLand Expression SA	FR	1800,00	Minority stake unknown %	Completed	Private Equity Venture capital Development capital	Cash	n.a.	n.a.
22	Otsuka Pharmaceutical Co., Ltd	JP FR	Nardobel SAS Mutabilis SA	FR FR	n.a.	Acquisition 100%	Completed	bereiopinent capital		n.a.	n.a.
24	Pharma Omnium International Rhône-Alpes Création SA Angel Investors Expansinvest Grenoble Angels Participations SAS Viaduc8	FR FR FR FR FR	SynapCell SAS	FR	n.a. 700,00	Acquisition 100% Minority stake unknown %	Completed Completed	Development capital Private Equity Angel Investment	Cash	n.a. n.a.	n.a. n.a.
25	Seventure Partners SA	FR	Polaris SAS	FR	6000,00	Minority stake unknown %	Completed	Development capital Private Equity	Cash	n.a.	n.a.
26 27	SGD SAS Silliker Inc.	FR US	Naturex SA Biofortis SA	FR FR	n.a. n.a.	Minority stake unknown % Acquisition 100%	Completed Completed			n.a. n.a.	n.a. n.a.
28	Société Générale	FR	Rhodia SA	FR FR	n.a.	Minority stake unknown %	Completed	Development control - 2 - 1 -	Cash	n.a.	n.a.
29	Sofinnova Partners Scottish Equity Partners Ltd Crédit Agricole Private Equity SA	FR GB FR	Stentys	FR	15 786,73	Minority stake unknown %	Completed	Development capital - 2nd round Venture capital	Cash	n.a.	n.a.
	Sofinnova Partners ALK-Abelló A/S	FR FR DK	DBV Technologies	FR	6000,00	Minority stake unknown %	Completed	Development capital Venture capital Corporate venturing	Cash	n.a.	n.a.
31 32	SpineGuard SA	FR	SpineVision SA's PediGuard business Naturex SA	FR FR	n.a. 17,300.00 *	Acquisition 100% Minority stake 22.331%	Completed Completed	Capital increase - rights issue	Cash	n.a. n.a.	n.a. 157 060,78
33			Quidd SAS	FR	n.a.	Minority stake unknown %	Rumour	Development capital Venture capital	Cash	n.a.	n.a.
34	-		Rhodia SA Zeta Biotech SA	FR FR	n.a. 1.400.00 *	Minority stake unknown % Minority stake unknown %	Completed Rumour	Capital increase	Cash	n.a. n.a.	n.a.
36	• •		lpsogen SAS	FR	1,400.00 * 2500,00	Minority stake 7.212%	Completed	Capital increase - placing	Cash	n.a.	n.a. 22 833,45
3/	•		Zeta Biotech SA	FR	763,00	Minority stake 14.286%	Announced	Capital increase	Cash	n.a.	5 340,89

	-		FINANCIAL BIOTR	ANSAC	TIONS I	N THE BRITISH ISLE	S FOR H1	2009			
	Acquiror name	Acquiror country code	Target name	Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment		Estimated Ent. value th EUR
1	3i Group plc	GB	MDY Healthcare plc	GB	472.34 *	Minority stake increased from 19.768% to 29.9%	Completed			n.a.	1 321,51
2	3i Group plc Seven Spires Investments (UK) Ltd ETF Manager LLP Chord Capital Ltd Cody Gate Ventures LLP	GB GB GB GB GB	Metalysis Ltd	GB	5 831,69	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
3	Abinqworth Management Ltd Wellcome Trust Ltd, The GlaxoSmithKline plc Essex Woodlands Health Ventures LP Nomura Phase4 Ventures Ltd Gilde Healthcare Partners BV	GB GB US GB NL	Chroma Therapeutics Ltd	GB	17 693,80	Minority stake unknown %	Completed	Development capital - 4th round Corporate venturing Venture capital	Cash	n.a.	n.a.
4 5 6	ACM Global Central Laboratory Operations Ltd AG Holding Ltd AGF Private Equity SA HBM BioVentures AG SPARK Ventures pIc Viking Technologies SA	GB GB FR CH GB CH	Pivotal Laboratories Ltd Axeon Holdings plc Vivacta Ltd	GB GB GB	n.a. n.a. 3 264,39	Acquisition 100% Acquisition 100% Minority stake unknown %	Completed Completed Completed	Venture capital Development capital	Cash	n.a. n.a. n.a.	n.a. n.a. n.a.
7	Allied Irish Banks plc	IE	Merrion Pharmaceuticals plc	IE	2066,00	Minority stake increased from 3.534% to 7.031%	Completed			n.a.	48 242,21
8	Audemat SA	FR	APT Ltd	GB	n.a.	Acquisition 100%	Completed			n.a.	n.a.
										(cont	inued p. 1

8

	Acquiror	Acquiror			All Deal values	S IN THE BRITISH IS	Deal		Deal method	Ent. valu	e Estimated
	name	country code	name	country code	th EUR	type	status		of payment	th EUR	Ent. value th EUR
	Auriga Partners SA Beringea Ltd	FR GB	Population Genetics Technologies Ltd	GB	6 585,61	Minority stake unknown %	Completed	Development capital - 1st round Venture capital	Cash	n.a.	n.a.
) 1	Compass Genetics Investors LLC Avacta Group plc Avacta Group plc	GB GB	Curidium Medica plc Theragenetics Ltd	GB GB	6,932.43 * 2,196.69 *	Acquisition 100% Acquisition 100%	Completed Completed		Shares Cash	n.a. n.a.	4 545,34 -451,29
)		GB	YorkTest Veterinary Services Ltd	GB	940,80	Acquisition 100%	Completed	Capital increase - vendor placing	Shares Deferred paymen		800,90
}	Azure Ventures Ltd	MT	Allergy Therapeutics plc	GB	15 386,04	Minority stake 40.704%		Capital increase - private placing	Cash Cash	n.a.	114 121,1
	Wild Indigo Mr Ignace Goethals	DK	Francisco Ital	CD	7 404 72	Minerity states unlessore 0/	Concluted	Venture evolted	Cash		
1		DK DE GB	Enecsys Ltd Tepnel Life Sciences plc	GB	7 104,72	Minority stake unknown % Minority stake unknown %	Completed Completed	Venture capital Development capital - 1st round	Cash Cash	n.a.	n.a. n.a.
5	Barclays plc	GB GB	ReGen Therapeutics plc	GB GB	n.a. 30.53 *	Minority stake increased from 5.673% to 8.513%	Completed		Casii	n.a. n.a.	1 105,61
	Directors	US	Lipoxen plc	GB	3 324,37	Minority stake 22.199%	Completed	Capital increase - private placing	Cash	n.a.	14 286,90
3	Management Institutional Investors Blue Star Capital plc	GB	Pedagog Ltd	GB	1 731,71	Minority stake	Completed	Capital increase - vendor placing	Shares	n.a.	n.a.
,	blue star capital pie	GD	OmniPerception Ltd Zimiti Ltd	GB GB GB		Minority State	compicted	cupital increase - vendor placing	Shares	n.u.	
	Brookwell Ltd Brookwell Ltd	GB GB	Plant Impact plc Surface Transforms plc	GB GB	320.93 * 105.46 *	Minority stake 6.726% Minority stake 4.241%	Completed Completed			n.a. n.a.	1 392,08 1 224,61
		GB	Surface Transforms plc	GB	67.77 *	Minoritý stake increased from 11.035% to 15.276%	Completed			n.a.	361,43
		GB GB	Cardiff Research Consortium Ltd CHKS Ltd CellAura Technologies Ltd	GB GB GB	15,360.41 * 567.88 *	Acquisition 100% Minority stake unknown %	Completed Completed	Development capital - 1st round	Cash	n.a. n.a.	n.a. n.a.
	Chanelle Veterinary Ltd	IE	PBS Sales Ltd	IE	4.000.00 *	Acquisition 100%	Completed	Venture capital	Casii	n.a.	4000.00
	Charterhouse Capital Partners LLP	GB	Wood Mackenzie Ltd	GB	649 904,14	Institutional buy-out 100%	Completed	New bank facilities Private Equity	Deferred payment	649 90	4,14 n.a
	Corporación Empresarial ONCE SA Hotspur Capital Partners Ltd	ES GB	Medalytix Ltd	GB	2 221,17	Minority stake unknown %	Completed	Development capital - 1st round Corporate venturing	Cash	n.a.	n.a.
	Cryo-Save Group NV	NL	Salus Futura Ltd	GB	400.00 *	Acquisition 100%	Completed	Venture capital	Earn-out Cash	n.a.	370,61
	Delphic Diagnostics Ltd Delta Partners Ltd	GB IF	iQur Ltd's diagnostics business Neoss Ltd	GB GB	n.a. 6 062,25	Acquisition 100% Minority stake unknown %	Completed Completed	Development capital	Cash	n.a. n.a.	n.a. n.a.
	Medtronic Inc. MMC Ventures Ltd	IE US GB		00	0 002/20		compicted	Corporate venturing Private Equity	cash		
	Individuals		SynAIRgen plc	GB	7,462.73 *	Acquisition 63.262%	Completed	Capital increase - private placing	Cash	n.a.	11 272,39
	Institutional Investors Directors	GB GB GB IN	Amarin Corporation plc	GB	1 855,15	Minority stake unknown %	Rumour	Capital increase - convertible loan notes	Cash	n.a.	n.a.
	Investors Elder Pharmaceuticals Ltd Employees	IN	NeutraHealth plc Allergy Therapeutics plc	GB GB	4,242.09 * 2,510.57 *	Acquisition increased from 21% to 60% Minority stake 6.642%	Withdrawn Completed	Capital increase - private placing	Cash	n.a. n.a.	19 979,38 114 119,7
	Shareholders	GB	Xeros Ltd	GB	1 079,64	Minority stake unknown %	Completed	Development capital	Cash	n.a.	n.a.
	Angel Investors	GB GB				,		Venture capital Angel Investment			
	Evolutec Group plc	GB GB DE	Nanoco Tech plc	GB	65,836.03 *	Acquisition 100%		Capital increase - vendor placing	Shares	n.a.	63 612,68
)	Evotec AG Existing Investors	DE	Summit Corporation plc's zebrafish services business Stabilitech Ltd	GB GB	567,82 3 565,41	Acquisition 100% Minority stake unknown %	Completed	Angel Investment	Cash Cash	n.a. n.a.	n.a. n.a.
	New investors Angel Investors		Stabiliteen Eta	UD	5 505,41	winonty state unknown 70	completeu	Development capital Venture capital	Cash	11.a.	11.a.
3	Individual Investors Finance Wales plc	GB GB	Ocelus Ltd	GB	53,07 270.39 *	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.
	National Assembly of Wales Ridings Early Growth Investment Company Ltd, The	GB GB GB			270.39 *	Minority stake unknown %	Completed	Venture capital Development capital	Cash	n.a.	n.a.
)	Fusion IP plc Finance Wales plc Fusion IP plc	GB GB	Mesuro Ltd	GB	1 161,63	Minority stake unknown %	Completed	Development capital - 1st round Venture capital	Cash	n.a.	n.a.
		GB GB	Renovo Group plc	GB	2,349.33 *	Minority stake increased from	Completed	venture cupitur		n.a.	-45 670,80
			Tepnel Life Sciences plc City Medical Services Ltd	GB	103,142.35 *	Minority stake increased from 14.358% to 19.387% Acquisition 100% Acquisition 100%			Cash	n.a.	100 670,5
	General Healthcare Group Ltd General Healthcare Group Ltd	US GB GB GB	City Medical Services Ltd St Luke's Hospital for the Clergy	GB GB GB	n.a. n.a.	Acquisition 100%	Completed Completed Completed		<b>C</b>	n.a. n.a.	n.a. n.a.
	GlaxoSmithKline plc	GB	Biotica Technology Ltd	GB	n.a.	Minority stake unknown %	Announced	Development capital - 4th round Venture capital Corporate venturing	Cash	n.a.	n.a.
ò	GlaxoSmithKline plc Hard to Treat Diseases Inc.	GB US	AstraZeneca plc Unnamed UK-based health	GB GB	35,192,161.92 n.a.	* Acquisition 100% Acquisition 100%	Rumour Rumour	Corporate venturing		n.a. n.a.	40891014,2 n.a.
		GB	care company Ceres Power Holdings plc	GB	2,085.64 *	Minority stake 2.683%	Completed			n.a.	47 842,23
	and Medicine Institutional Investors		Silence Therapeutics plc	GB	2 920,90	Minority stake 10.978%		Capital increase - placing Capital increase - private placing	Cash	n.a.	22 914,42
)	Institutional Investors Integrated DNA Technologies	BE	Allergy Therapeutics plc VH Bio Ltd	GB GB GB	8 365,83 n.a.	Minoritý stake 22.132% Acquisition 100%	Completed Completed Completed	Capital increase - private placing	Cash	n.a. n.a.	114 121,0 n.a.
3	International Specialty Products Inc. Inverness Medical Innovations Inc.	US US	Ionic Solutions Ltd's certain assets Concateno plc	GB	n.a. 144,476.68 *	Acquisition 100% Acquisition 100%	Completed	Capital increase - vendor placing	Shares Cash	n.a. n.a.	n.a. 137 951,8
ł		BM	BTG plc	GB	5,024.19 *	Minority stake increased from 21.989% to 23.133%	Completed			n.a.	350 350,0
5	INVESCO Perpetual UK Investment Series Ltd Imperial Innovations Ltd	GB GB GB	Nexeon Ltd	GB	11 081,46	Minority stake unknown %	Completed	Venture capital Development capital	Cash	n.a.	n.a.
)	PUK Ventures Investors	GB GB GB	ReGen Therapeutics plc	GB GB	73,01 60,45	Minority stake 11.98% Minority stake 8.811%	Completed	Capital increase - placing	Cash	n.a.	639,79 716,91
5	Investors		ReGen Therapeutics plc ReGen Therapeutics plc Timestrip plc	GB GB GB	60,45 71,87 681,32	Minority stake 8.811% Minority stake 9.456% Minority stake 8.193%	Completed Completed	Capital increase - placing Capital increase - placing Capital increase - placing	Cash Cash Cash	n.a. n.a. n.a.	790,32 7 446,15
)	Investors	GB GB	Ebiox Ltd	GB	801,69	Minority stake 36.8%			Cash	n.a.	3 906,77
	Mr John Honey Japan Tobacco Inc.	GB JP	Tribac Leaf Ltd	GB	n.a.	Acquisition 100%	Announced			n.a.	n.a.
-	Judges Scientific plc	GB	Quorum Technologies Ltd	GB	1,738.85 *	Acquisition 100%	Completed		Cash Earn-out	n.a.	1 007,96
}	Kisco Ltd Kisco Ltd	GB GB	Evolutec Group plc Evolutec Group plc	GB GB	537.96 * 185.43 *	Minority stake 9.05% Minority stake increased from 9.05% to 12.163%	Completed Completed		Cash Cash	n.a. n.a.	-559,73 -547,43
5	Lab 21 Ltd Lab 21 Ltd	GB GB	Biotec Laboratories Ltd Plasmatec Laboratory Products Ltd	GB I GB	n.a. n.a.	Acquisition unknown majority stake % Acquisition 100%	Completed Completed			n.a. n.a.	n.a. n.a.
ò	Legal & General Group plc	GB	BTG plc	GB	5,407.53 *	Acquisition unknown majority stake % Acquisition 100% Minority stake increased from 2.397% to 3.898%	Completed		Cash	n.a.	297 434,8
3		GB	SSL International plc	GB	5,954.25 *	3.622% to 4.117%	Completed	Development of the state	Cash	n.a.	1 314 966,8
9	Management Imperial Innovations Group plc	GB GB	Navion Pharma Ltd	GB	n.a.	Minority stake unknown %	Completed	Development capital - seed Venture capital	Cash	n.a.	n.a.
)	Management Imperial Innovations Ltd	GB GB	Veryan Medical Ltd	GB	2 777,36	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.

To subscribe, please call Biotech Finances Customer Service et + 33 478 24 35 20. Copiright © 2009 Ed Européennes de l'Innovation. Reporoductions is stricly prohibited. Visit our website at www.biotech-finances.xcom

10



					NS IN THE BRITISH IS					
Acquiror name	Acquiro country		country	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR
1 MBO Team - United Kingdom	GB	Quantum Specials Ltd	code ' GB	36 094,09	Management buy-out 100%	Completed	New bank facilities		n.a.	35 002,44
72 MDY Healthcare plc	GB	ProStrakan Group plc	GB	1,592.47 *	Minority stake 1.224%	Completed	Private Equity Capital increase - vendor placing	Shares	n.a.	129 042,19
								Loan notes Cash		
'3 Midven Ltd	GB	Cytox Ltd	GB	701,30	Minority stake unknown %	Completed	Development capital - seed	Deferred payment Cash	n.a.	n.a.
Angel Investors Masa Inc.	US						Venture capital Angel Investment			
4 Mobile Inspiration Ltd	GB	Mobile Inspiration Ltd and Saturn Communications Group Ltd's technolog	GB y joint ve	n.a. Inture	Joint venture 100%	Announced			n.a.	n.a.
Saturn Communications Group Ltd 5 MonoBank plc	GB GB	UK Logic plc	GB	n.a.	Acquisition 100%	Pending - av	vaiting regulatory approval			n.a. n.a.
6 Mr C Moreno	GB	55 1 1	GB	310.00 *	Minority stake increased from 4.209% to 7.178%	Completed		Cash	n.a.	79 507,79
7 Mr Graham Platts 8 Mr Ivor Harrison	MC GB	Timestrip plc William Ransom & Son plc	GB GB	478,43 112.43	Minority stake 11.627% Minority stake 3.439%	Completed Completed	Capital increase - placing	Cash Cash	n.a. n.a.	3 262,83 10 681,67
9 Mr Peter Gyllenhammar	SE	MDY Healthcare plc	GB	112,43 301.05 *	Minority stake increased from 15.675% to 21.052%	Completed			n.a.	1 868,93
0 Mr Thomas Hirth 1 MVM Life Science Partners LLP	GB	Axeon Holdings plc Alliance Pharma plc	GB GB	106.58 * 779.87 *	Minority stake 5.097% Minority stake 9.256%	Completed Completed		Cash	n.a. n.a.	8 101,90 40 774,44
2 National Institute of Agricultural Botany	GB US	Arable Group Ltd, The Lab 21 Ltd	GB GB	n.a. 1 410,19	Acquisition 100% Minority stake unknown %	Rumour Completed	Development capital	Cash	n.a. n.a.	n.a. n.a.
Nexus Medical Partners     Medicis Capital GMBH     Novartis Venture Fund	DE	Immune Targeting Systems (ITS) Ltd		6 353,13	Minority stake unknown %	Completed	Private Equity Development capital - 1st round	Cash	n.a.	n.a.
HealthCap AB Company Guides Venture Partners Ltd	CH SE GB	initiatie raigeting systems (115) Eta	UD	0 555,15	WINDITY STAKE UNKNOWN 70	completeu	Venture capital	Casii	11.a.	11.d.
Truffle Capital	FR	Oncono Thereneutics Ltd	IF.	21200.00	Minerity stake unknown 0/	Completed	Corporate venturing	Cash		
5 Novartis Venture Fund Enterprise Ireland	IE	Opsona Therapeutics Ltd	IE	21300,00	Minority stake unknown %	Completed	Development capital - 2nd round Venture capital	Cash	n.a.	n.a.
Inventages Venture Capital GmbH Roche Venture Fund, The	CH CH						Corporate venturing			
Fountain Healthcare Partners Ltd Seroba Kernel Life Sciences Ltd	IE IE									
6 Novartis Venture Fund Clarus Ventures LLC	CH US	Heptares Therapeutics Ltd	GB	23 953,29	Minority stake unknown %	Completed	Corporate venturing Venture capital	Cash	n.a.	n.a.
MVM Life Science Partners LLP 7 Octopus Investments Ltd	GB GB	e-Therapeutics plc	GB	1 031,61	Minority stake 5.383%	Completed	Development capital - 1st round Capital increase - private placing	Cash	n.a.	17 019.56
8 OP-Rahastoyhtiö Oy 9 Orexo AB	FI		GB GB	7,428.00 * n.a.	Minority stake 5.507% Acquisition 100%	Completed Completed	Capital increase - vendor placing	Earn-out	n.a. n.a.	88 643,88 n.a.
	52		00	11.0.	Acquisition 10070	completed	cupital increase - vendor placing	Cash Shares	11.0.	11.0.
0 Orient Pharma Ltd		Summit Corporation plc	CP	262.02	Minority stake 4%	Completed	Capital increases private placing	Deferred payment	n	2 222,47
<ol> <li>Oxford Capital Partners Inc.</li> </ol>	US	Summit Corporation plc Sirigen Ltd	GB GB	362,92 1 410,54	Minority stake 4% Minority stake unknown %	Completed Completed	Capital increase - private placing Development capital	Cash Cash	n.a. n.a.	z zzz,47 n.a.
Seraphim Capital (GP) Ltd Oxford Gene Technology Ltd Oxford Technology Venture Capital Trust plu	GB GB	Sense Proteomic Ltd	GB	n.a.	Acquisition 100%	Completed	Venture capital	<b>C</b>	n.a.	n.a.
Management	GB GB GB	Warwick Effect Polymers Ltd	GB	1 092,31	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
West Midlands Enterprise Ltd Catapult Venture Managers Ltd	GB GB									
Private Investors 4 Oxford Technology Venture Capital Trust pl	c GB	ImmunoBiology Ltd	GB	8000,00	Minority stake unknown %	Completed	Development capital - 3rd round	Cash	n.a.	n.a.
Avlar Bioventures Ltd YFM Private Equity Ltd	GB GB						Venture capital			
Inventages Venture Capital Investments Inc Hygea VCT plc										
Chord Capital Ltd 5 PharmaCare Group	GB AU	Healthcare Brands International	GB	n.a.	Acquisition 100%	Completed			n.a.	n.a.
	AU	Ltd's Sambucol brand					Development capital	Cash		
6 Private equity investors	6.0	, ,	GB	n.a.	Minority stake unknown %	Completed	Private Equity	Cash	n.a.	n.a.
7 Quotient Bioresearch Ltd (new)	GB	Charles River Laboratories International Inc.'s Edinburgh-based dinical research	facility	n.a.	Acquisition 100%	Completed			n.a.	n.a.
8 Quotient Bioresearch Ltd (new) 9 Roundstone Properties Ltd	GB GB	Amersham Radiolabeling Service Proton Power Systems plc	GB	n.a. 2 236,39	Acquisition 100% Minority stake 24.572%		Capital increase - private placing	Cash	n.a. n.a.	n.a. 7 966,41
00 Sagem Sécurité SA	FR	CardBASE Technologies Ltd's intellectual property, equipment and business		2250,00	Acquisition 100%	Completed		Cash	n.a.	n.a.
01 SC Green Tech Ventures LLC	US	'AC'AL Énergy Ltd	GB	n.a.	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
02 Scottish Enterprise	GB	Antoxis Ltd	GB	324,85	Minority stake unknown %	Completed	Corporate venturing Development capital Venture capital	Cash	n.a.	n.a.
02 Scottish Enterprise Tri Capital Ltd Kapital Venture Equity LLP	GB GB GB						Venture capital Angel Investment			
Kapital Venture Equity LLP Grampian BioPartners Ltd 03 Scottish Enterprise	GB	Centeo Biosciences Ltd	GB	740,95	Minority stake unknown %	Completed		Cash	n.a.	n.a.
Grainball BioFardiels Lud S Scottish Enterprise Strathclyde University Incubator Ltd Tri Capital Ltd LINC Scotland Highland Venture Capital Limited 4 Shackleton Ventures Ltd	GB GB GB GB GB	centeo bioscences eta	00	140,55	winonty state unknown 70	completed	Development capital Venture capital Angel Investment	Cush	11.0.	11.0.
LINC Scotland	GB						Anger investment			
04 Shackleton Ventures Ltd 05 Shareholder	GB	NanoSight Ltd ReGen Therapeutics plc	GB GB	n.a. 34,63	Minority stake increased from 7.5% to	15% Completed	Completed	Private Equity		n.a. n.a. 949,84
05 Shareholder 06 Shareholder 07 Shareholders 08 Shareholders	GB	ReGen Therapeutics pic ReGen Therapeutics pic Henderson Morley pic ReGen Therapeutics pic NextGen Group pic's non core electrophoresis business	GB GB	34,03	Minority stake increased from 7.5% to Minority stake 3.769% Minority stake 3.568% Minority stake 20.242%	Announced	Capital increase - private placing Capital increase - private placing	Cash Cash	n.a. n.a.	949,84 1 023,65 822,05
08 Shareholders	GB	ReGen Therapeutics plc	GB	35,39 323,70 27.20 *	Minority stake 3.4%	Completed	Capital increase - private placing Capital increase - private placing Capital increase - private placing Capital increase - private placing	Cash Cash	n.a. n.a.	822,05 830,74 882,67
09 Shareholders 10 Sigma-Aldrich Corporation	GB US	NextGen Group plc's non core	GB GB	66,79 445,80	Minority stake 3.4% Minority stake 7.834% Acquisition 100%	Completed Completed	Capital increase - private placing	Cash Cash	n.a. n.a.	882,67 n.a.
11 Star Clinical Systems Ltd	GB	electrophoresis business Synermed Europe Ltd's assets	GB	111.74 *	Acquisition 100%	Completed		Cash	n.a.	n.a.
12 StemCells Inc.	US	Synermed Europe Ltd's assets Stem Cell Sciences plc's trading subsidiaries and certain assets	GB	3,661.22 *	Acquisition 100%	Completed	Capital increase - vendor placing	Shares Deferred payment	n.a.	n.a.
13 Takeda Ireland Ltd	IE	Takeda Pharma Ireland Ltd	IE	n.a.	Acquisition 100%	Announced		Converted Debt	n.a.	n.a.
14 Tarsus Group plc	GB	CapRegen plc	GB	3,660.35 *	Acquisition increased from 17.406% to 100%	Completed	Capital increase - vendor placing	Shares	n.a.	n.a. 291,99
15 ThromboGenics NV 16 Toshiba Medical Visualisation Systems Europe Ltc	BE	ThromboGenics Ltd Barco NV's Advanced Visualisation	IE GR	n.a.	Acquisition increased from 100% to 100% Acquisition 100%	Completed Completed			n.a.	n.a. n.a.
, ,		Imaging System Division		n.a.				Cash	n.a.	
7 UBS	CH		GB	1,324.27 *	Minority stake increased from 1.629% to 5.174%	Completed	Developmentit-l	Cash	n.a.	162 437,63
8 University of Bath Investors	GB GB	Azellon Ltd	GB	1 813,63	Minority stake unknown %	Completed	Development capital - seed Venture capital	Cash	n.a.	n.a.
Wellcome Trust Ltd, The	GB GB GB									
IP Group plc Oxford Technology Management Ltd Wyvern Seed Fund LP	GB GB									
Wyvern Seed Fund LP 9 Unnamed European biological reseach comp.	GB		Rinding 9	šite Ltd's auto-imm	une division The	GB	94,933.13 *	Acquisition 100%	Rumour	
9 Onnamed European biological reseach comp. a. n.a. 10 Williams de Broë Ltd	,	Omena Diagnostics Group pla	5							4 882,81
	GB		GB	557.1Z	7.995% to 18.919%	Completed			n.a.	·
21 WPP plc 22 - 23 -	GB	Red Dot Square Solutions Ltd Elan Corporation plc Plethora Solutions Holdings plc Cambridge Biotechnology Ltd SSL International plc	GB IE GB	11.a. 4,000,000.00 *	Minority stake increased from 7.995% to 18.919% Acquisition 100% Acquisition 100% Minority stake unknown %	Completed Rumour	6 N.L.	Debt assumed	n.a. 4000000,00	
23 -		Piethora Solutions Holdings plc	GB GB	1 066,69 n.a.	Minority stake unknown % Acquisition 100% Minority stake 9.122%	Announced Rumour	Capital increase - convertible loan	notes	Cash	n.a. n.a.
24 - 25 -		Californuge biotechnology Ltu	GB	98,825.99 *			Capital increase - placing	Cash	n.a. n.a.	n.a. 1 195 432,15

(continued p.12)



	FINANCIAL BIO	TRAN	SACTION	S IN THE BRITISH ISL	ES FOR I	11 2009			
Acquiror Acquiro name country code	name	country code	th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR
126 - 127 -	Vectura Group plc Immune Targeting Systems (ITS) Ltd	GB GB	10,198.40 * n.a.	Minority stake 3.368% Minority stake unknown %	Completed Rumour	Development capital - 2nd round Venture capital	Cash Cash	n.a. n.a.	217 946,40 n.a.
128 - 129 - 130 -	Axis-Shield plc Axis-Shield plc Tepnel Life Sciences plc Futura Medical plc	GB GB GB	2,170.57 * 1,508.31 * 382.49 *	Minority stake 1.226% Minority stake 0.928% Minority stake 2.013%	Completed Completed Completed	Capital increase		n.a. n.a. n.a.	185 309,26 170 485,17 16 519,87 18 669,20
131 - 132 - 133 -	Ivy Medical Chemicals plc Charles River Laboratories International Inc.'s Riccarton testing facility	GB GB	1,460.81 * 92.68	Minority stake 2,203% Minority stake 2,013% Minority stake 2,013% Acquisition 100% Acquisition 100% Minority stake 0,293% Minority stake 0,293%	Completed Completed Announced	Capital increase - placing	Cash Cash	n.a. n.a. n.a.	841,34 n.a
134 - 135 - 136 -	Intercytex Group plc Shire plc Futura Medical plc ReNeuron Group plc	GB GB GB	n.á. 12,318.22 * 15,449.35 * 1,080.43 *	Acquisition 100% Minority stake 0.293% Minority stake 7.985%	Withdrawn Completed Completed	Capital increase - placing	Cash	n.a. n.a. n.a.	7 467,19 5 337 632,46 12 685,82
137 - 138 - 139 -	Abcam plc Tepnel Life Sciences plc	GB GB GB	1,080.43 * 3 430,41 1,175.59 * 1,514.32 *	Minority stake 0.295% Minority stake 29.424% Minority stake 0.574% Minority stake 2.095%	Completed Completed Completed	Capital increase - placing Capital increase	Cash Cash Cash	n.a. n.a. n.a.	12 685,82 8 356,20 190 839,63 69 869,12
140 - 141 - 142 - 143 -	Neuropharm Group plc Valirx plc ProStrakan Group plc	GB GB GB GB	2,448.82 * 634.37 * 5,142.70 * 55,356.64 *	Minority stake 49.837% Minority stake 4.209%	Rumour Completed Completed	Capital increase - placing	Cash Cash	n.a. n.a. n.a.	n.a. 1 179,91 121 102,84
144 - 145 -	Renovo Group plc Cobra Biomanufacturing plc Immupharma plc	GB GB		Acquisition unknown stake % Acquisition unknown stake % Minority stake 2.71%	Rumour Withdrawn Completed		Cash	n.a. n.a. n.a.	n.a. n.a. 55 057,49
146 - 147 - 148 - 149 -	Immupharma plc Valirx plc Valirx plc	GB GB GB GB	55,536.04 1,525.33 * 1 828,16 1 828,16 225,70 355.46 * 120.22 * 224,92 858.00 * 27.15 46 *	Minority stake 2.71% Minority stake 14.602% Minority stake 17.185%	Completed Completed Completed	Capital increase - placing	Cash Cash	n.a. n.a. n.a.	n.a. 55 057,49 55 057,49 1 449,30 1 975,48 3 180,34
150 -	Valirx plc 3D Diagnostic Imaging plc Optos plc Vernalis plc	GB GB	120.22 224,92 858.00 * 27.125.46 *	Acquisition unknown stake % Minority stake 2.71% Minority stake 2.71% Minority stake 17.02% Minority stake 17.085% Minority stake 3.069% Initial public offering 2.921% on PLUS Minority stake 3.193% Acquisition 68.75% Minority stake 2.017% Minority stake 2.017% Minority stake 2.017%	Completed Completed Completed	Capital increase - placing Capital increase - rights issue	Cash Cash	n.a. n.a. n.a. n.a.	n.a. 46 950,27 42 547,61 7 033,37 1 720,25
152 - 153 - 154 - 155 -	Phynoxa Group plc Phynoxa Group plc Archimedes Pharma Ltd	GB GB GB GB	27,125.46 * 235.32 * 609,84	Minority stake 2.017% Minority stake 28.401%	Completed Completed Completed Rumour	Capital increase Capital increase Capital increase - placing	Cash	n.a. n.a. n.a.	7 033,37 1 720,25
155 - 156 - 157 - 158 -	Valinx plc SSL International plc SkyePharma plc	GB GB GB	n.a. 223,08 1,840.88 * 2,306.69 *	Acquisition 100% Minority stake 23.924% Minority stake 0.183% Minority stake 2.396%	Completed Completed Completed	Capital increase - placing Capital increase Capital increase	Cash	n.a. n.a. n.a.	n.a. 837,65 1 026 048,65 225 500,80
159 - 160 -	Valinx pic Henderson Morley pic SSL International pic Oxford Biosensors Ltd	GB GB	1,119.56 * 733.38 * 2,089.96 *	Minority stake 61.75% Minority stake 24.942% Minority stake 0.183% Acquisition 100%	Announced Completed Completed	Capital increase - placing Capital increase - public offer Capital increase	Cash Cash	n.a. n.a. n.a.	1 715,85 2 119,09 1 162 571,83
161 - 162 - 163 - 164 -	Öxford Biosensors Ltd BTG plc Proximagen Neuroscience plc Epistem Holdings plc	GB GB GB GB	n.a. 1,755.70 * 58.441.74 *	Acquisition 62.333%	Rumour Completed Completed Completed	Capital increase - placing	Cash	n.a. n.a. n.a.	n n
165 - 166 - 167 -	SSL International plc York Pharma plc	GB GB GB	805.49 * 2,033.32 * 64.57 *	Minority stake 2.765% Minority stake 0.183% Minority stake 3.745%	Completed	Capital increase		n.a. n.a. n.a.	27 601,03 83 222,59 26 767,65 1 131 882,40 -3 754,80 239 496,37
168 - 169 - 170 -	SkyePharma plc Goldshield Group plc Chroma Therapeutics Ltd	GB GB GB	2 925,80 135,186.26 * n.a.	Minority stake 2.814% Acquisition unknown stake % Planned IPO unknown stake %	Completed Rumour Rumour	Capital increase		n.a. n.a. n.a.	n.a. n.a.
171 - 172 -	Alizyme plc Provexis plc	GB GB	n.a. 268.26 *	Minority stake unknown % Minority stake 2.885%	Rumour Completed	Capital increase		n.a. n.a.	n.a. 8 671,36

		FINANCIAL BIOTRANSACTIO	) NS I	N THE G	GERMANIC COUN	<b>TRIES FO</b>	R H1 2009			
Acquiror name	Acquiror country code		Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment		Estimated Ent. value th EUR
1 Advanced Micro Devices Inc.	US	Advanced Mask Technology Center GmbH & Co. KG	G DE	n.a.	Acquisition increased from	Rumour			n.a.	n.a.
					66.67% to 100%					
Toppan Photomasks Inc.	US									
2 Akzo Nobel NV		LII Europe GmbH		n.a.	Acquisition 100%	Completed			n.a.	n.a.
3 Alcon Inc.	CH	Wavelight AG	DE	n.a.	Acquisition increased from	Announced		Cash	n.a.	n.a.
4 Alexa las	C11	Marylinhe A.C.	DE	C C 1 F 00 *	77.4% to 95%	Annessed		Cash		100702.00
4 Alcon Inc.	СН	Wavelight AG		6,615.00 *	Acquisition increased from 95% to 100%	Announced		Cash	n.a.	160792,00
5 Analytik Jena AG	DE	CyBio AG	DE	275.00 *	Minority stake 5.482%	Completed			n.a.	5 695,42
6 Analytik Jena AG	DE	CyBio AG	DE	2,320.00 *	Acquisition increased from 5.482% to 51.185%	Completed			n.a.	5 755,25
7 Analytik Jena AG	DE	CyBio AG	DE	2,900.00 *	Acquisition increased from	Rumour		Cash	n.a.	6 619,80
					51.185% to 100%					
8 Analytik Jena AG	DE	Biometra biomedizinische Analytik GmbH	DE	n.a.	Acquisition 100%	Announced		Cash	n.a.	n.a.
9 Ascenion GmbH	DE	MBiotec GmbH	DE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
10 Atlas Venture UK Ltd	GB	ProtAffin Biotechnologie AG	AT	14000,00	Minority stake unknown %	Completed	Development capital - 2nd round	Cash	n.a.	n.a.
SR One Ltd	GB						Corporate venturing			
Entrepreneurs Fund BV	NL						Venture capital			
Aescap Venture Management BV	NL									
Z-Cube Srl	IT									
11 Baigo Capital GmbH	DE	VANGUARD AG	DE	n.a.	Minority stake unknown %	Completed	Private Equity Development capital	Cash	n.a.	n.a.
12 Bausch & Lomb Inc.	US	Technolas Perfect Vision GmbH	DE	n.a.	Joint venture 100%	Completed			n.a.	n.a.
20/10 Perfect Vision AG	DE									
13 Biofrontera AG's certain shareholders		Biofrontera AG		500.00 *	Minority stake 9.36%	Completed	Capital increase - private placing	Cash	n.a.	26 387,43
14 BioNTech AG (Mainz)	DE	EUFETS AG		n.a.	Acquisition 100%	Completed			n.a.	n.a.
15 BioScience Ventures Group AG	DE	APEPTICO Forschung und Entwicklung GmbH	AT	1000,00	Minority stake unknown %	Completed	Development capital - seed Angel Investment Venture capital	Cash	n.a.	n.a.
16 Biotropics Malaysia Bhd		InterMed Discovery GmbH	DE	7440,00	Minority stake unknown %	Completed		Cash	n.a.	n.a.
17 bm-t Beteiligungsmanagement Thüringen GmbH		Analytik Jena AG	DE	2,496.00 *	Minority stake 7.545%	Announced	Capital increase - private placing	Cash	n.a.	39 002,51
18 Carl Zeiss Industrielle Messtechnik GmbH	DE	Holometric Technologies Forschungs- und Entwicklungs-GmbH	DE	n.a.	Acquisition 100%	Completed			n.a.	n.a.
19 Conduit Ventures Ltd Shareholders	GB	Heliocentris Fuel Cells AG	DE	4000,00	Minority stake 19.162%	Completed	Capital increase - rights issue Capital increase - private placing	Cash	n.a.	18 908,65
20 Cytotools AG	DE	DermaTools Biotech GmbH	DE	n.a.	Minority stake unknown %	Completed	Capital increase - private placing	Cash	n.a.	n.a.
21 Deutsche Venture Capital GmbH	DE	KeyNeurotek Pharmaceuticals AG	DE	8200,00	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.
tbg Technologie-Beteiligungs-Gesellschaft mbH							Development capital			
IBG Beteiligungsgesellschaft Sachsen-Anhalt mb-	1 DE									
Investors										

(continued p.13)



		FINANCIAL BIOTRANSACTIO	ONS	IN THE (	GERMANIC COUNT	RIES FO	R H1 2009			
Acquiror name	Acquiro country code			All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	e Estimated Ent. value th EUR
22 Deutsche Venture Capital GmbH IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH KfW Bankengruppe	DE	KeyNeurotek Pharmaceuticals AG	DE	8200,00	Minority stake unknown %	Completed	Development capital - 3rd round Venture capital	Cash	n.a.	n.a.
	DE	Agrarmarkt Informations-GmbH	DE	n.a.	Minority stake unknown %	Rumour			n.a.	n.a.
Investors	DE	Agrarmarkt Informations-GmbH	DE	n.a.	Joint venture 100%	Completed			n.a.	n.a.
Landwirtschaftsverlag GmbH	DE DE	CDC Distoch AC	DE	25 722 00 *	Acquisition 1000/	Announced	Capital increase - vendor placing	Charac		FC1F 00
	DE	GPC Biotech AG Sygnis Pharma AG	DE DE	5197,00	Acquisition 100% Minority stake increased from 36.156% to 44.904%	Announced Completed	Capital increase - vendor placing	Shares Cash	n.a. n.a.	5615,00 57 306,87
27 Dr. Willmar Schwabe GmbH & Co. KG	DE	Dr. Peithner Holding GmbH	AT	n.a.	Acquisition 100%	Completed			n.a.	n.a.
28 Elektrobit Oyj	FI	Elektrobit Oyj and Audi Electronics Venture GmbH's unnamed infotainment joint venture	DE	n.a.	Joint venture 100%	Announced			n.a.	n.a.
29 Enjoyventure Management GmbH	DE DE	Rodos BioTarget GmbH	DE	n.a.	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.
30 Entrepreneurs Fund BV	DE NL	Vasopharm Biotech GmbH	DE	4500,00	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
KfW Bankengruppe EMBL Ventures GmbH	DE DE	Dr					Development capital - 4th round			
HeidelbergCapital Asset Management Gmb 31 EPG AG	H DE	DE Kraiburg Geotech GmbH	DE	n.a.	Acquisition increased from	Completed			n.a.	n.a.
32 Fraunhofer-Gesellschaft zur Förderung	DE	-	DE		75.05% to 100% Acquisition 100%	Rumour				
der angewandten Forschung eV		Forschungsgesellschaft für Angewandte Naturwissenschaften eV		n.a.					n.a.	n.a.
	DE	Phenion GmbH & Co. KG	DE	n.a.	Acquisition increased from 100% to 100%	Completed			n.a.	n.a.
CFH Beteiligungsgesellschaft mbH	DE DE	pluriSelect GmbH	DE	600,00	Minority stake unknown %	Completed	Venture capital Development capital	Cash	n.a.	n.a.
35 IC Green Energy Ltd	IL	Petrotec AG	DE	1050,00	Minority stake 9.091%	Completed	Capital increase - private placing	Cash	n.a.	28 845,50
36 IMD Institut für Medizinische Diagnostik GmbH	DE	Medizinisches Labor Rostock Müller Nordmed GmbH Dr Matic und Kollegen GbR Labormedicus GmbH	DE DE DE DE	18,401.68 *	* Minority stake	Completed			n.a.	n.a.
37 Institutional Investors		Epigenomics AG	DE	5182,00	Minority stake 9.087%	Completed	Capital increase - private placing	Cash	n.a.	44 964,52
38 Institutional Investors		Mologen AG	DE	2763,00	Minority stake 4.363%	Completed	Capital increase - private placing	Cash	n.a.	60 007,99
39 Investors	DE	LD Didactic GmbH	DE	n.a.	Institutional buy-out 80%	Pending - awaiting regu	Private Equity latory approval		n.a.	n.a.
Aurelius AG 40 KGHM Cuprum Sp zoo Centrum	DE PL	KGHM HMS Bergbau AG	DE	n.a.	Joint venture 100%	Completed			n.a.	n.a.
Badawczo - Rozwojowe	DE		DL	11.a.	Joint venture 100 /6	Completed			11.a.	11.d.
41 Koninklijke DSM NV	NL	Biopract GmbH	DE	n.a.	Acquisition 100%	Completed			n.a.	n.a.
42 Labco SAS 43 Management	FR DE	AescuLabor-Karlsruhe GmbH P 21 GmbH - Power for the 21st Century	DE DE	n.a. 10000,00	Acquisition 100% Minority stake unknown %	Completed Completed	Development capital	Cash	n.a. n.a.	n.a. n.a.
Target Partners GmbH Conduit Ventures Ltd	DE GB	T 21 Glibh - Tower for the 21st century	DL	10000,00	winonty state unknown /o	completed	Venture capital	Cash	11.a.	11.d.
Yellow&Blue Investment Management BV 44 MannKind Corporation	NL US	Pfizer Inc's insulin facility at Industriepark	DE	26 035,75	Acquisition 100%	Withdrawn	Capital increase - vendor placing	Shares	n.a.	n.a.
		Hoechst, Frankfurt am Main, Germany and related								
45 Mr Ady Palti	DE	Curasan AG Operon Biotechnologies GmbH	DE		Minority stake 4.21% Acquisition 100%	Completed			n.a.	10 714,87
46 MWG Biotech AG 47 Palladius Healthcare GmbH	DE DE	Precisis AG	DE DE	n.a. n.a.	Acquisition 96.28%	Completed Completed			n.a. n.a.	n.a. n.a.
48 Precisis AG	DE	Stryker Leibinger GmbH & Co. KG's radiotherapy	DE	n.a.	Acquisition 100%	Completed			n.a.	n.a.
49 Roche Holding AG	СН	business unit innovatis AG	DE	15000,00	Acquisition 100%	Pending -			n.a.	13 362,97
50 Sächsische Landesbank Corporate Finance	DE	UroTec GmbH	DE	n.a.	Minority stake unknown %	awaiting shar Completed	eholder approval Development capital	Cash	n.a.	n.a.
Holding GmbH 51 Sanofi-Aventis Deutschland GmbH	DE	Pfizer Inc's insulin facility at Industriepark Hoechst,	DE	30000,00	Acquisition 100%	Announced	Venture capital		n.a.	n.a.
	DE	Frankfurt am Main, Germany and related assets Jerini AG	DE	7,456.00 *	Acquisition increased from	Pending -		Cash	n.a.	441 208,52
					98.32% to 100%	awaiting shar	eholder approval	00071		
	DE DE	Geohumus International GmbH Invitek Gesellschaft für Biotechnik & Biodesign mbH	DE I DE	n.a. 3,465.00 *	Minority stake 30% Acquisition 100%	Completed Completed	Capital increase - vendor placing	Shares Earn-out Cash	n.a. n.a.	n.a. 3 798,49
55 Technische Universität Dresden	DE	Namlab GmbH	DE	n.a.	Acquisition increased from 50%		Rumour			n.a. n.a.
56 Theracode GmbH	DE	JPT Peptide Technologies GmbH	DE	5,000.00 *	Acquisition 100%	Announced	Control in an	Cash	n.a.	102 173,80
57 UCB Pharma SA 58 UCB SP GmbH	BE DE	Wilex AG Schwarz Pharma AG	DE DE	10000,00 21,722.00 *	Minority stake 22.991% Acquisition increased from 99.59% to 100%	Announced Rumour	Capital increase - private placing	Cash Cash	n.a. n.a.	31 358,28 5 776 551,78
59 Unnamed European Company		RESprotect GmbH	DE	n.a.	Minority stake 10%	Completed		Cash	n.a.	n.a.
60 -		Biofrontera AG	DE	3000,00	Minority stake 37.618%	Completed	Capital increase - private placing Capital increase - rights issue	Cash	n.a.	29 020,46
61 -		Biofrontera AG	DE	20000,00	Minority stake unknown %	Completed	Capital increase - convertible bond		Cash	n.a. n.a.
62 -		AAP Implantate AG	DE	1,267.00 *	Minority stake 4.545%	Announced	Capital increase - private placing	Cash	n.a.	40 905,79
63 - 64 -		Cytotools AG ItN Nanovation AG	DE DE	2420,00 530,00	Minority stake 8.621% Minority stake 8.965%	Completed Announced	Capital increase - private placing Capital increase	Cash Cash	n.a. n.a.	27 005,98 5 358,88
65 -		Brahms Diagnostica GmbH	DE	n.a.	Minority stake 0.505 %	Rumour	prost mercuse		n.a.	n.a.
66 -		Sovello AG	DE	n.a.	Minority stake 33.333%	Rumour			n.a.	n.a.
67 -		Biofrontera AG	DE		Minority stake 31.053%	Announced	Capital increase - rights issue Capital increase	Cash	n.a.	28 262,25
68 - 69 -		ItN Nanovation AG Beiersdorf AG	DE DE	1478,00 366,001.00 *	Minority stake 20% Minority stake 4.32%	Completed Completed	Capital increase - rights issue	Cash	n.a. n.a.	6837,00 7 208 245,37



ſ	~		FINANCIAL BIOT	RANS	ACTIONS IN	N SWITZERLAND	FOR H1 2	2009			
	Acquiror name	Acquiror country code		Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment		Estimated Ent. value th EUR
1	Abingworth Management Ltd Investor Growth Capital AB Novo A/S Aravis General Partner Ltd Versant Venture Management LLC Sam Ventures LLC Swiss Helvetia Fund Inc., The	GB SE DK CH US US US	Synosia Therapeutics	СН	21 676,03	Minority stake unknown %	Completed	Venture capital Development capital - 2nd round	Cash	n.a.	n.a.
2	BB Biotech AG Atlas Venture UK Ltd HealthCap AB Endeavour Vision SA BioMed Invest AG	CH GB SE CH CH	Lumavita AG	СН	15 946,05	Minority stake unknown %	Completed	Development capital - 1st round Venture capital	Cash	n.a.	n.a.
3	BB Biotech AG Matignon Investissement et Gestion SAS Signet Healthcare Partners LLC	CH FR US	Anteis SA	СН	4 605,24	Minority stake unknown %	Completed	Development capital - 2nd round Venture capital	Cash	n.a.	n.a.
4	BP Alternative Energy	GB	South Pole Carbon Asset Management Ltd	CH	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
5	BZ Bank AG	СН	NovImmune SA	СН	41 467,02	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
6	CBC Schweiz AG	СН	Konso, Institut für Konsumenten- und Sozialanalysen AG	СН	n.a.	Minority stake 34%	Completed	Capital increase - private placing	Cash	n.a.	n.a.
7	Covance Inc.	US	Swiss Pharma Contract Ltd	CH	n.a.	Acquisition 100%	Completed			n.a.	n.a.
8	Existing Investors		AC Immune SA	СН	26 478,63	Minority stake unknown %	Completed	Venture capital Development capital - 3rd round	Cash	n.a.	n.a.
9	Existing Investors		Kenta Biotech AG	СН	8 106,79	Minority stake unknown %	Completed	Development capital - 2nd round Venture capital	Cash	n.a.	n.a.
10	Grifols SA	ES	Medion Diagnostics AG Woolamaloo Holdings Pty Ltd	CH AU	25000,00	Acquisition	Announced	Capital increase - private placing	Cash	n.a.	n.a.
	Hervé Thermique SAS	FR	Alvazzi	CH	n.a.	Acquisition 100%	Completed			n.a.	n.a.
12	Index Venture Management SA Sofinnova Partners Edmond de Rothschild Investment Partners SAS	CH FR FR	GlycoVaxyn AG	СН	16 924,73	Minority stake unknown %	Completed	Development capital - 2nd round Venture capital	Cash	n.a.	n.a.
	MDY Healthcare plc	GB	Santhera Pharmaceuticals Holding AG	СН	1,592.47 *	Minority stake 1.423%	Completed	Capital increase - vendor placing	Loan notes Shares Cash Deferred pay		63 036,99
14	Private Investors		Axentis Pharma AG	CH	n.a.	Minority stake unknown %	Completed		Cash	n.a.	n.a.
	QureInvest AG	СН	CT Atlantic AG	CH	6 773,76	Minority stake unknown %	Completed	Development capital - 1st round Venture capital	Cash	n.a.	n.a.
	Sanofi-Aventis SA	FR	Helvepharm AG	CH	n.a.	Acquisition 100%	Announced			n.a.	n.a.
17	Shareholders Mr Willy Michel Techpharma Management AG	СН СН	Ypsomed Holding AG	СН	63 404,27	Minority stake 11.111%	Completed	Capital increase - converted debt Capital increase - rights issue	Converted Deb Cash	ıt n.a.	570 644,15
18			AC Immune SA	СН	n.a.	Acquisition 100%	Rumour			n.a.	n.a.
19	•		ImVisioN Therapeutics AG	СН	n.a.	Minority stake unknown %	Rumour	Venture capital Development capital - 2nd round	Cash	n.a.	n.a.
20			Nycomed International Management GmbH	CH	10,000,000.00 *	Acquisition 100%	Rumour			n.a.	1000000,00
21	-		Arpida AG	CH	n.a.	Minority stake unknown %	Rumour			n.a.	n.a.

#### FINANCIAL BIOTRANSACTIONS IN NORDIC COUNTRIES FOR H1 2009

FINANCIAL BIOTRANSACTIONS IN NORDIC COUNTRIES FOR H1 2009											
Acquiror name		quiror Intry I le		Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment		e Estimated Ent. value th EUR
1 Affitech A/S	DK		Affitech Research AS	NO	12,898.63 *	Acquisition 100%	Announced	Capital increase - vendor placing	Shares	n.a.	11 896,66
2 Arbejdsmarkedets Tillægspens ATP Invest	sion DK RU		Bavarian Nordic A/S	DK	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
3 Arbeidsmarkedets Tillægspens ATP Invest	sion DK RU		LifeCycle Pharma A/S	DK	3,471.32 *	Minority stake 5.09%	Completed			n.a.	-10 203,95
4 Avanza Bank Holding AB	SE		Karo Bio AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
5 Avanza Bank Holding AB	SE	l	Diamyd Medical AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
6 Biovitrum AB Karolinska Development AB	SE SE		Biovitrum AB and Karolinska Development AB's leukemia joint venture	SE	n.a.	Joint venture 100%	Announced	Private Equity		n.a.	n.a.
7 Bitten & Mads Clausens Fond			Danfoss IXA A/S	DK	n.a.	Joint venture 100%	Completed	Private Equity		n.a.	n.a.
Danfoss Ventures A/S	DK							riivale Equily			
8 Cadring Oy	FI		Arkins Suunnittelu Oy	FI	n.a.	Acquisition 100%	Completed		cl	n.a.	n.a.
9 Catech AB	SE		PSD Insight AB	SE	810.31 *	Acquisition 100%	Announced	Capital increase - vendor placing	Shares	n.a.	859,46
10 Chalmers Innovation	SE		Orthocone	SE	27,17	Minority stake unknown %	Completed		Cash	n.a.	n.a.
11 CRGMD Holdings	IE			SE	n.a.	Acquisition 100%	Completed			n.a.	n.a.
12 Davidoff A/S	DK		Notox Systems A/S' activities	DK	n.a.	Acquisition 100%	Completed			n.a.	n.a.
13 Det Norske Veritas AS Gassco AS	NC NC		Gassco AS andDet Norske Veritas AS' pipeline inspection joint venture	NU	n.a.	Joint venture 100%	Completed			n.a.	n.a.
14 DnBNOR Kapitalforvaltning AS			Algeta ASA	NO	2.713.60 *	Minority stake 13.471%	Completed			n.a.	5 452,36
15 DONG Energy A/S Project Better Place LLC	DK US		Better Place Denmark A/S	DK	103000,00	Minority stake unknown %	Completed	Capital increase - convertible bond issue Capital increase - private placing	Cash	n.a.	n.a.
16 Duroc AB	SE		SSAB Tunnplåt AB's Hard and Special Steels unit in Lule	i SE	n.a.	Acquisition 100%	Completed	1 1 3		n.a.	n.a.
17 Econet Engineering Oy	FI	,	YIT Oyj's water and engineering service unit	FI	n.a.	Acquisition 100%	Announced			n.a.	n.a.
18 Ecopower Skandinavia AS	NC			NO	n.a.	Minority stake 13.04%	Completed			n.a.	n.a.
19 Eli Lilly and Company	US		NeuroSearch A/S	DK	13 315,50	Minority stake 3.261%	Completed	Capital increase - private placing	Cash	n.a.	380 494,88
20 Enics AG	CH		Sweco Industry Oy's Industrial Electronics Service unit	FI	n.a.	Acquisition 100%	Completed			n.a.	n.a.
21 EXFO Electro-Optical Engineer	ring Inc. CA		PicoSolve AB	SE	n.a.	Acquisition 100%	Completed			n.a.	n.a.
22 Existing Investors Essex Woodlands Health Vent	ures LP US		Symphogen A/S	DK	33000,00	Minority stake unknown %	Completed	Development capital Private Equity	Cash	n.a.	n.a.
23 Genovis AB	SE		Eijdo research AB	SE	459,54	Acquisition 100%	Announced	Capital increase - vendor placing	Cash Shares	n.a.	n.a.
24 GlaxoSmithKline plc	GB		NeuroSearch A/S	DK	5 001,21	Minority stake 2.077%	Completed	Capital increase - private placing	Cash	n.a.	212 924,13
25 H Lundbeck A/S	DK		Neuronicon ApS	DK	n.a.	Acquisition 100%	Completed			n.a.	n.a.
26 HealthCap AB Suomen itsenäisyyden juhlarahast Life Sciences Partners BV Suomen Teollisuussijoitus Oy Teknologian kehittämiskeskus	NL FI		Nexstim Oy	FI	3000,00	Minority stake unknown %	Completed	Venture capital Capital increase - convertible bond issue Development capital	Cash	n.a.	n.a.

(continued p.15)



To subscribe, please call Biotech Finances Customer Service et + 33 478 24 35 20. Copiright © 2009 Ed Européennes de l'Innovation. Reporoductions is stricly prohibited. Visit our website at www.biotech-finances.xcom

Acquiror name	Acquiron country	r Target	Target country	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment		Ent. value
27 Hebi Holding AB	code SE	Hebi Health Care AB	code SE	7,371.91 *	Acquisition increased from 9.2% to 100%	Withdrawn		Cash	n.a.	th EUR 30 691,08
28 Hebi Holding AB 29 Ignis ASA	SE NO	Hebi Health Care AB Syntune AB	SE SE	7,470.01 * 5 053,63	Acquisition increased from 9.2% to 100% Acquisition 100%	Withdrawn Pending -	Capital increase - vendor placing	Cash Shares Debt assum		31 099,50 32 678,51
30 Industrifonden SLS Invest AB	SE SE	Gyros AB	SE	7 299,51	Institutional buy-out unknown stake %	Completed	eholder approval Private Equity Development capital	Cash	n.a.	n.a.
31 Institutional Investors 32 Institutional Investors	JL	DiaGenic ASA Clavis Pharma ASA	NO NO	1 028,42 14 317,10	Minority stake 4.609% Minority stake 44.184%	Completed Completed	Capital increase - private placing Capital increase - private placing	Cash Cash	n.a. n.a.	19 238,11 22 948,41
33 Investor 34 Investor AB	SE	Scandivir AB Biovitrum AB	SE SE	668,33 51 263,73	Minority stake 9% Minority stake 21.4%	Announced Completed	Private Equity	Cash	n.a. n.a.	7 425,85 169 443,96
35 Investors		7TM Pharma A/S	DK	11,406.00 *	Minority stake unknown %	Completed	Private Equity Development capital	Cash	n.a.	n.a.
36 Investors Östersjöstiftelsen	SE SE	Morphic Technologies AB	SE	3 136,02	Minority stake 9.07%	Completed	Capital increase - private placing	Cash	n.a.	15 990,17
37 Investors 38 Investors 39 Investors		NattoPharma ASA Affitech A/S Oasmia Pharmaceutical AB	NO DK SE	798,73 3 600,43 8,130.23 *	Minority stake 8.909% Minority stake 15.104%	Announced Completed Announced	Capital increase - private placing Capital increase - private placing	Cash Cash Cash	n.a. n.a.	7 004,47 18 992,75
40 Investors 41 IPC International A/S	DK	Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB NatImmune A/S	SE DK	8,130.23 * 6 716,14	Minority stake unknown % Minority stake unknown % Acquisition 100%	Announced Completed	Capital increase - private placing Capital increase - private placing Capital increase - vendor placing	Cash Shares	n.a. n.a. n.a.	n.a. n.a. 6 130,22
42 Karolinska Development AB	SE	EvoStem Finland Oy	FI	n.a.	Minority stake unknown %	Completed	Private Equity Development capital	Cash	n.a.	n.a.
43 Karolinska Development AB Lund University Bioscience AB	SE SE	ProNoxis AB	SE	n.a.	Minority stake unknown %	Completed	Private Equity Development capital	Cash	n.a.	n.a.
44 Länsförsäkringar Fondförvaltning AB 45 LFI A/S	SE DK	Medivir AB LifeCycle Pharma A/S	SE DK	n.a. 37 003,58	Minority stake unknown % Minority stake increased from 1.002% to 28	Completed 8.208%	Completed		n.a.	n.a. n.a.
57609,00 46 MedCap AB	SE	Handitek AB	SE	599,73	Institutional buy-out 33%	Completed	New bank facilities		n.a.	1 419,53
47 Medtronic Inc.	US	PreciSense A/S's glucose monitoring assets		n.a.	Acquisition 100%	Completed	Private Equity	<b>C</b>	n.a.	n.a.
48 Merck KGaA 49 Molex Inc.	DE US	MediCult A/S Motorola Inc.'s Antenna/EMC	DK DK	43,911.25 * n.a.	Acquisition 100% Acquisition 100%	Withdrawn Completed		Cash	n.a. n.a.	57 789,52 n.a.
50 Mr Carsten Waern 51 Mr Leif Pihlqvist's unnamed company	SE	Measurement Lab equipment assets Scandivir AB IDL Biotech AB	SE SE	302,44 n.a.	Minority stake 3.3% Acquisition unknown stake %	Rumour Completed		Other	n.a. n.a.	9 164,80 n.a.
52 Nordnet AB 53 Nordnet Pensionsförsäkring AB	SE SE	Karo Bio AB Karo Bio AB	SE SE SE	n.a. n.a.	Minority stake unknown % Minority stake unknown %	Completed Completed			n.a. n.a.	n.a. n.a.
54 Northzone Ventures AB Hafslund Venture AS	SE NO	ChapDrive AS	NO	5 959,67	Minority stake unknown %	Completed	Venture capital Development capital	Cash	n.a.	n.a.
Energy Capital Management BV Innovasjon Norge	NL NO									
StatoilHydro Venture AS 55 Northzone Ventures AB	NO Se	Imbera Electronics Oy	FI	11 221,74	Minority stake unknown %	Completed	Private Equity	Cash	n.a.	n.a.
Conor Venture Partners Oy Index Venture Management Ltd	FI GB						Development capital - 2nd round			
56 Öhrlings PricewaterhouseCoopers AB 57 Opcon AB	SE SE	IM-Gruppen i Uppsala AB Saxlund Holding AB	FI SE	n.a. 8,758.15 *	Acquisition 100% Acquisition 100%	Completed Completed	Capital increase - vendor placing	Shares	n.a. n.a.	n.a. 6 877,47
58 OSI (Prosidion) Ltd	GB	7TM Pharma A/S's early stage discovery assets and technology	DK	n.a.	Acquisition 100%	Completed		Cash	n.a.	n.a.
59 Pilum AB 60 Q-Cells SE	SE DE	Hyheat AB Solibro AB	SE SE	n.a. 115000,00	Minority stake unknown % Acquisition increased from 64.3% to 100%	Rumour Announced	Capital increase - vendor placing	Cash	n.a. n.a.	n.a. 321 898,84
61 Rocksource Geotech AS	NO	GeoContrast AS	NO	805,95	Minority stake 33.4%	Announced	Capital increase - converted debt	Shares Converted Deb		2 160,53
62 SEB Investment Management AB 63 Shareholders		Vitrolife AB Algeta ASA	SE NO	n.a. 27 110,62	Minority stake unknown % Acquisition 57.457%	Completed Completed	Capital increase - private placing	Cash	n.a. n.a.	n.a. 32 492,52
Investors Abingworth LLP	GB	-								
64 Sjätte AP-fonden	SE	Accumulate AB	SE	n.a.	Minority stake unknown %	Completed	Private Equity Development capital	Cash	n.a.	n.a.
65 Skellefteå Kraft AB Outotec Oyj 3 unnamed Swedish companies	SE FI SE	GreenExergy AB	SE	n.a.	Joint venture 100%	Announced			n.a.	n.a.
66 Sofinnova Partners Northzone Ventures AB	FR SE	ReVolt Technology AS	NO	5500,00	Minority stake unknown %	Completed	Development capital Private Equity	Cash	n.a.	n.a.
Viking Venture AS SINTEF Venture AS	NO NO						Thruce Equity			
TVM Capital GmbH Verdane Capital	DE NO									
RWE Innogy GmbH 67 Suomen Teollisuussijoitus Oy	DE FI	Epicrystals Oy	FI	6000,00	Institutional buy-out 13%	Completed	Private Equity	Cash	n.a.	46 779,85
VNT Management Óy 68 Svolder AB	FI SE	XANO Industri AB	SE	n.a.	Minority stake unknown %	Completed	Private Equity			n.a.
69 Tredje AP-fonden 70 Tuotekehitys Oy Tamlink	SE FI	Orexo AB Teknologiakeskus Hermia Oy's business	SE FI	n.a. n.a.	Minority stake unknown % Acquisition 100%	Completed Announced			n.a.	n.a. n.a.
71 UPM-Kymmene Oyj Stora Enso Timber Oy Ltd Ruukki Group Oyj	FI FI FI	Finnish Wood Research Oy	FI	n.a.	Joint venture 100%	Completed			n.a.	n.a.
Ekovilla Oy Metsäliitto-konserni	FI									
Tikkurila Oy 72 VækstFonden	FI DK	Playdead	DK	1 476,16	Minority stake unknown %	Completed	Development capital	Cash	n.a.	n.a.
Centre for Advanced Technology Scien			DK						Venture	capital
FAHU Fonden 73 Valtion Teknillinen Tutkimuskeskus	DK FI	Keskuslaboratorio Oy - Centrallaboratorium	Ab's resea	arch and laborat	ory operations	FI	n.a.	Acquisition	100%	Rumour
74 Vattenfall AB	n.a. SE	n.a. Vattenfall AB and Vovo Personvagnar Holdin	ıg AB's ele	ectric car joint v	enture	SE	n.a.	Joint ventur	e 100%	Completed
Volvo Personvagnar Holding AB 75 Vitrolife AB	n.a. SE SE	n.a. MediCult A/S	DK	33,120.82 *	Acquisition 100%	Withdrawn	Capital increase - vendor placing	Shares	n.a.	46 992,25
76 Wilhelm Sihn Jr GmbH & Co. KG 77 -	DE	A2B Electronics AB Genovis AB	SE SE	53,120.82 n.a. 940.06 *	Acquisition 100% Acquisition 100% Minority stake 23.185%	Completed	Capital increase - vendor placing	Cash	n.a.	40 992,25 n.a. 4 439,03
77 - 78 - 79 -		NorDiag ASA Scandinavian Clinical Nutrition i Sverige AB	NO	3 793,03 819,48	Acquisition 55.709% Minority stake 24.518%	Completed Completed	Capital increase - rights issue Capital increase - private placing	Cash Cash	n.a. n.a.	5 278,54 4 890,28
80 - 81 -		NicoNovum AB Karo Bio AB	SE SE	4 316,21 n.a.	Minority stake unknown % Minority stake unknown %	Rumour Completed	Capital increase - placing	Cash		n.a. n.a.
82 -		Lytix Biopharma AS	NO	7 852,78	Minority stake unknown %	Completed	Venture capital Development capital	Cash		n.a.

(continued p.16)



		FI	NANC	IAL BIOTR	ANSACTIONS IN NORDIC C	OUNTRIE	S FOR H1 2009			
	Acquiror country code	Target name	Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR
83 -	couc	Biophausia AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
84 -		Biolight AB	SE	501,88	Minority stake 50%	Announced	Capital increase - rights issue	Cash	n.a.	251 068,64
85 -		Guideline Oil Drilling Technology AB	SE	658,81	Minority stake 11.713%	Completed	Capital increase - rights issue	Cash	n.a.	5 701,33
86 -		Genmab A/S	DK	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
87 - 88 -		ALK-Abelló A/S	DK SE	n.a.	Minority stake unknown %	Completed	Capital ingrassa	Cash	n.a.	n.a.
89 -		Clinical Laserthermia Systems AB NeuroVive Pharmaceutical AB	SE	451,75 564.91 *	Initial public offering 11.086% on AktieTorget Minority stake 6.4%	Completed Completed	Capital increase	Cash	n.a. n.a.	4 051,11 8 797,21
90 -		Algeta ASA	NO	542,25	Minority stake 0.470 Minority stake 1.08%	Completed	Capital increase - rights issue	Cash	n.a.	34 743,23
91 -		LifeAssays AB	SE	1 057,72	Minority stake 20%	Completed	Capital increase - rights issue	Cash	n.a.	4 211,91
92 -		Aerocrine AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
93 -		Tigran Technologies AB	SE	1,829.33 *	Minority stake 33.661%	Announced	Capital increase - rights issue	Cash	n.a.	4 136,76
94 -		TopoTarget A/S	DK	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
95 -		Ortoma AB	SE	93,34	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
96 - 97 -		Nycomed Holding ApS	DK	n.a. 55.18 *	Planned IPO unknown stake %	Rumour			n.a.	n.a.
97 - 98 -		Scandinavian Clinical Nutrition i Sverige AB	SE Fl	9.750.00 *	Minority stake 2.247%	Completed	Capital ingrasca	Cach	n.a.	4 002,94
98 - 99 -		Elektrobit Oyj Agellis Group AB	SE	9,750.00 613.74 *	Minority stake 16.19% Minority stake 43.717%	Rumour Completed	Capital increase Capital increase - rights issue	Cash Cash	n.a. n.a.	13 985,36 457,56
100-		Aqua Bio Technology ASA	NO	837.59 *	Minority stake 41.464%	Announced	Capital increase - private placing	Cash	n.a.	1 865,33
101-		Aqua Bio Technology ASA	NO	522,50	Minority stake 27.77%	Rumour	Capital increase - converted debt	Converted Debt	n.a.	1 726,23
102 -		Aqua Bio Technology ASA	NO	n.a.	Minority stake unknown %	Rumour	Capital increase - rights issue	Cash	n.a.	n.a.
103 -		Aerocrine AB	SE	n.a.	Minority stake 10%	Rumour			n.a.	n.a.
104 -		Scandivir AB	SE	2,135.40 *	Minority stake 23.3%	Rumour			n.a.	9 164,80
105-		Scandivir AB	SE	2,044.08 *	Minority stake 22%	Completed		Other	n.a.	9 291,28
106-		BankInvest's biotechnology portfolio	DK	n.a.	Minority stake unknown %	Rumour		6.1	n.a.	n.a.
107-		Active Biotech AB	SE	24,325.22 *	Minority stake 20%	Announced	Capital increase - rights issue	Cash	n.a.	132 984,76
108 - 109 -		Biotage AB Dignitana AB	SE SE	n.a. 1 306,79	Minority stake unknown % Initial public offering 40.636% on AktieTorget	Announced Completed	Capital increase - public offer Capital increase - rights issue	Cash	n.a. n.a.	n.a. 3 129,87
110-		Vitrolife AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
111-		Biovitrum AB's non-core research activities	SE	n.a.	Acquisition 100%	Rumour			n.a.	n.a.
112-		Active Biotech AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
113-		Tigran Technologies AB	SE	1 869,62	Minority stake unknown %	Completed	Capital increase - rights issue	Cash	n.a.	n.a.
114-		LightLab Sweden AB	SE	1,023.25 *	Acquisition 50%	Completed	Capital increase - rights issue	Cash	n.a.	769,22
115-		Aqua Bio Technology ASA	NO	520,48	Minority stake 27.77%	Announced	Capital increase - converted debt	Converted Debt	n.a.	1 719,55
116- 117-		Medi-Stim ASA Opcon AB	NO SE	3,890.70 * 1,192.26 *	Minority stake 9.091% Minority stake 1.47%	Rumour Completed	Capital increase	Cash	n.a. n.a.	40 517,25 91 521,93
118-		Biotage AB	SE	4,427.05 *	Minority stake 9.045%	Rumour	Capital increase	Cash	n.a.	11 966,38
119-		Vitrolife AB	SE	4,378.14 *	Minority stake 8.965%	Rumour	Capital increase	Cash	n.a.	47 840,25
120 -		NattoPharma ASA	NO	9,639.88 *	Acquisition unknown stake %	Rumour			n.a.	n.a.
121-		Nolato AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
122 -		Active Biotech AB	SE	23829,00	Minority stake 20%	Completed	Capital increase - rights issue	Cash	n.a.	130 271,99
123 -		Meda AB	SE	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
124-		Swedish Orphan International AB	SE	350,000.00 *	Acquisition 100%	Rumour			n.a.	348645,00
125-		Orexo AB	SE FI	n.a.	Minority stake unknown % Acquisition 100%	Completed			n.a.	n.a.
126 - 127 -		Encorium Oy Artimplant AB	SE	n.a. n.a.	Minority stake unknown %	Rumour Completed			n.a. n.a.	n.a. n.a.
128-		DNA-Guide Europa AB	SE	940.97 *	Minority stake unknown %	Announced	Capital increase	Cash	n.a.	n.a.
129-		Ortivus AB	SE	1,024.72 *	Minority stake 10.092%	Rumour	Capital increase	Cash	n.a.	8 107,27
130-		Duroc AB	SE	3,930.63 *	Minority stake 30.063%	Rumour	Capital increase	Cash	n.a.	8 840,21
131 -		TopoTarget A/S	DK	17,811.30 *	Acquisition 50%	Completed	Capital increase - rights issue	Cash	n.a.	21 116,91
132 -		Meda AB	SE	17,115.46 *	Minority stake 1.1%	Completed			n.a.	2 970 826,70
133-		Meda AB	SE	40,960.37 *	Minority stake 2.647%	Rumour			n.a.	2 970 720,27
134 -		BioGaia AB Biophauria AB	SE SE	4,311.10 *	Minority stake 4.367%	Completed	Capital increase rights issue	Cach	n.a.	94 645,15
135- 136-		Biophausia AB MediCult A/S	DK	5 887,18 4,260.90 *	Minority stake unknown % Minority stake 8.977%	Completed Rumour	Capital increase - rights issue Capital increase	Cash Cash	n.a. n.a.	n.a. 61 345,54
130- 137-		Pronova BioPharma ASA	NO	4,200.90	Minority stake 8.415%	Rumour	cupital increase	Cash	n.a.	676 353,67
138-		TPS Termiska Processer AB	SE	n.a.	Acquisition 100%	Rumour		cush	n.a.	n.a.
139-		Arcam AB	SE	2,700.82 *	Acquisition 57.143%	Completed	Capital increase - rights issue Capital increase - placing	Cash	n.a.	4 884,73
140-		BioTie Therapies Oyj	FI	8,750.00 *	Minority stake 14.765%	Rumour	Capital increase	Cash	n.a.	69 559,77
141 -		InvivoSense ASA	NO	n.a.	Minority stake unknown %	Rumour	Capital increase	Cash	n.a.	n.a.
142 -		Biovitrum AB	SE	n.a.	Minority stake unknown %	Completed	Conital ingrases within items	Cash	n.a.	n.a.
143 - 144 -		Tigran Technologies AB	SE SE	138,06	Minority stake 5.21%	Announced	Capital increase - rights issue	Cash	n.a.	1 289,57
144 - 145 -		Karo Bio AB Oasmia Pharmaceutical AB	SE	n.a. 5,403.98 *	Minority stake unknown % Minority stake 6.667%	Completed Announced	Capital increase - rights issue	Cash	n.a. n.a.	n.a. 83 020,07
145-		Clavis Pharma ASA	NO	903,02	Minority stake 4.568%	Completed	Capital increase - private placing	Cash	n.a.	9 905,70
140-		NattoPharma ASA	NO	2,297.16 *	Minority stake 18.215%	Rumour	Capital increase	Cash	n.a.	10 717,91
148-		Biovitrum AB	SE	2 190,08	Minority stake 0.791%	Completed	Capital increase	Cash	n.a.	206 450,07
149 -		BioInvent International AB	SE	5,320.24 *	Minority stake 4%	Completed			n.a.	113 328,06
150 -		Genline Holding AB	SE	n.a.	Minority stake unknown %	Rumour	Capital increase	Cash	n.a.	n.a.
151-		IPC International A/S	DK	11,279.81 *	Minority stake unknown %	Completed	Capital increase - private placing	Cash	n.a.	n.a.
							· · · · · -			/

#### FINANCIAL BIOTRANSACTIONS IN THE BENELUX FOR H1 2009

	name	Acquiror country code		Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR
1	Akzo Nobel NV	NL	Salinco VOF	NL	n.a.	Acquisition unknown stake %	Pending -			n.a.	n.a.
							awaiting regulatory a	approval			
2	BAM Techniek BV	NL	Digacom BV	NL	n.a.	Acquisition 100%	Announced			n.a.	n.a.
3	Bondholders		Pharming Group NV	NL	9700,00	Minority stake 8.219%	Completed	Capital increase - private placing	Cash	n.a.	135 275,22
	Yorkville Advisors LLC	US									
4	Crédit Agricole Private Equity SA	FR	FlexGen BV	NL	n.a.	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.
	BioGeneration Ventures BV	NL						Development capital			
5	Eckert & Ziegler Strahlen und Medizintechnik AG	DE	International Brachytherapy SA	BE	54,931.00 *	Acquisition increased from 29.89% to 100%	Rumour		Cash	n.a.	88 986,74
6	Eneco NV	NL	Ecofys Netherlands BV	NL	n.a.	Acquisition 100%	Pending -			n.a.	n.a.
							awaiting regulatory a				
7	Existing Investors		Cardio3 BioSciences SA	BE	7200,00	Minority stake unknown %	Completed	Development capital - 2nd round	Cash	n.a.	n.a.
	Grifols SA	ES						Venture capital			
	New investors							Corporate venturing			
	Life Sciences Research Partners VZW	BE									
	Hunza Ventures	BE									
	Unnamed venture capital company	LU									



To subscribe, please call Biotech Finances Customer Service et + 33 478 24 35 20. Copiright © 2009 Ed Européennes de l'Innovation. Reporoductions is stricly prohibited. Visit our website at www.biotech-finances.xcom

Acquiror	Acquiror	Tarnet	Target	All Deal values	Deal	Deal	Deal	Deal method	Ent value	Estimated
name	country	name	country	th EUR	type	status	financing	of payment	th EUR	Ent. value
GIMV NV	code BE	ActoGenix NV	code BE	13500,00	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	th EUR n.a.
VenTech SA	FR	Acto Genix IIV	DL	15500,00	minority stake unknown /s	completed	Development capital	cush	11.0.	11.0.
Life Sciences Partners BV	NL									
Biotech Fund Flanders	BE									
Baekeland Funds	BE									
, 3,	BE									
Aescap Venture Management BV	NL BE									
Biovest Comm.VA GIMV NV	BE	Pronota NV	BE	4900,00	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.
Johnson & Johnson Development Corporation		FIUIULA INV	DL	4900,00	WINDING STARE UNKNOWN 70	Completed	Development capital - 2nd round		II.d.	11.a.
Life Sciences Partners BV	NL						Development capital 2nd round			
Biotech Fund Flanders	BE									
Baekeland Funds	BE									
Flanders Interuniversity Institute for Biotechnology	BE									
KBC Private Equity NV	BE									
) GIMV NV	BE	Liquavista BV	NL	5000,00	Minority stake unknown %	Completed	Private Equity	Cash	n.a.	n.a.
Amadeus Capital Partners Ltd	GB						Development capital - 3rd round			
Prime Technology Ventures NV 1 GlaxoSmithKline plc	NL GB	UCB SA's certain	BE	515000,00	Acquisition 100%	Announced		Cash	n.a.	n.a.
	UD	smaller market activities	DL	515000,00	Acquisition 100 %	Announceu		Casil	II.d.	11.d.
2 IJB Geotechniek BV	NL	Flevo Geotechniek BV	NL	n.a.	Acquisition 100%	Completed			n.a.	n.a.
	NL	TiGenix NV	BE	5400,00	Minority stake 4.21%	Completed	Private Equity	Cash	n.a.	104 310,03
LRM Limburg Investment Company	BE						Capital increase			.,
Limburg Ventures BV	NL									
	NL									
4 Innoven Partenaires SA	FR	OctoPlus NV	NL	702,00	Minority stake 2.592%	Completed	A7 . 6.1	Cash	n.a.	45 565,33
5 Katholieke Universiteit Leuven	BE	Formac Pharmaceuticals N\	/ BE	2100,00	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.
Allegro Investment Fund Vlaams Innovatiefonds	BE BE						Development capital			
Gemma Frisius - Fonds KU Leuven	BE						Corporate venturing			
Hunza Ventures	BE									
Life Science Research Partners	BE									
5 KEMA NV	NL	Gasunie Engineering & Technology BN	/ NL	n.a.	Acquisition 100%	Announced			n.a.	n.a.
7 Life Sciences Fund Amsterdam BV	NL	AIMM Therapeutics BV	NL	n.a.	Minority stake unknown %	Completed	Development capital	Cash	n.a.	n.a.
							Venture capital			
8 LSP III Management BV	NL	OctoPlus NV	NL	2337,00	Minority stake increased from 12.87% to 17.21%			Cash	n.a.	72 329,93
9 Management	NL	OctoPlus NV	NL	6000,00	Minority stake 33.048%	Completed	Capital increase - private placing	Cash	n.a.	36 637,41
	US	Dutch Lonistics Development	+ D\/	All		A	Conselated			
	NL US	Dutch Logistics Developmen Bestewil Holding BV	NL	NL n.a.	n.a. Acquisition 100%	Acquisition 100% Announced	Completed	Loan notes	<b>n</b> 0	n.a. n.a
1 Mymetics Corporation	03	Destewii noiuliiy DV	INL	II.d.	Acquisition 100%	Announceu		Cash	n.a.	n.a.
								Earn-out		
2 NOM Fin. BV	NL	Plastinum Polymer Technologies	s NL	n.a.	Minority stake unknown %	Completed	Private Equity	Cash	n.a.	n.a.
		Corp BV's operational plant			,		Development capital			
3 Noord-Brabant Development Agency	NL	Validus Technologies BV	NL	n.a.	Minority stake 20%	Completed	Private Equity		n.a.	n.a.
4 NTS-Group	NL	Systence BV	NL	n.a.	Acquisition 100%	Completed			n.a.	n.a.
	NL	Bluestream NL BV	NL	n.a.	Acquisition 100%	Completed			n.a.	n.a.
6 Participatiemaatschappij Oost Nederland NV		Ceradis BV	NL	n.a.	Minority stake 10%	Completed	Private Equity		n.a.	n.a.
7 ProChemie Holding	DE	,	NL	n.a.	Acquisition 50%	Pending - awaiting	regulatory approval	Cash		n.a. n.a
8 Sanofi-Aventis Europe 9 SR One Ltd	FR GB	Zentiva NV OctoPlus NV	NL NL	1,208,366.77 * 2,336.00 *	Acquisition unknown majority stake % Minority stake 9.889%	Completed Completed	Private Equity	Cash Cash	n.a.	n.a. 42 104,21
D SSL International plc	GB	Beleggingsmaatschappij Lemore BV		2,550.00 n.a.	Acquisition increased from 50% to 100%		rivale equily	CdSII	n.a. n.a.	42 104,21 n.a.
1 SSL International plc	GB		NL	70000,00	Acquisition increased from 15.5% to 50%			Cash	n.a.	202 898,55
	0.5	Lemore BV		,,	plus one share	completed		cash		202 050,55
2 Sysmex Corporation	JP	Sysmex Nederland BV	NL	n.a.	Acquisition	Announced			n.a.	n.a.
3 Sysmex Corporation	JP	Sysmex Belgium NV	BE	n.a.	Acquisition 100%	Announced			n.a.	n.a.
4 Waterland Private Equity Investments BV	NL	Enfinity	BE	50000,00	Institutional buy-out unknown majority st		Completed	Private Equity	Cash	n.a. n.a
5 YA Global Master SPV Ltd		Pharming Group NV	NL	20,000.00 *	Minority stake 4.99%	Announced	Capital increase - private placing		n.a.	418 057,60
5 YA Global Master SPV Ltd		Pharming Group NV	NL	600,00	Minority stake 1.068%	Completed	Capital increase - private placing		n.a.	73 435,78
7 YA Global Master SPV Ltd		Pharming Group NV	NL	400,00	Minority stake 0.707%	Completed	Capital increase - private placing		n.a.	73 833,09
8 - 9 -		Pharming Group NV Crucell NV	NL NL	4000,00 1,021,815.00 *	Minority stake 1.531% Acquisition 100%	Completed Rumour	Capital increase - convertible bond issue	CdSII	n.a.	278 523,15 911597,00
) - )		Omega Pharma SA	BE	4940,00	Acquisition 100% Minority stake 0.85%	Completed		Cash	n.a. n.a.	911597,00
1 -		OctoPlus NV	NL	n.a.	Minority stake unknown %	Announced	Capital increase - convertible loa		Cash	n.a. n.a
2 -		ActoGenix NV	BE	2000,00	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a. n.a
				,	,	,	Development capital			
3 -		Solvay Pharma BV	NL	5,500,000.00 *	Acquisition 100%	Rumour			n.a.	5499996,00
4 -		Ablynx NV	BE	168,510.00 *	Acquisition unknown stake %	Rumour			n.a.	n.a.
5 -		Fornix Biosciences NV's	NL	n.a.	Acquisition 100%	Rumour			n.a.	n.a.
5 -		certain assets ThromboGenics NV	BE	3100,00	Minority stake 2.268%	Completed	Capital increase -	Cash	n.a.	77 763,30
7 -		Schering-Plough	NL	8,000,000.00 *	Acquisition 100%	Rumour	convertible bond issue		n.a.	n.a.
		Corporation's animal health								
-		Solvay Pharma BV	NL	n.a.	Planned IPO unknown stake %	Rumour			n.a.	n.a.
) -		Pharming Group NV	NL	8000,00	Minority stake 7.306%	Completed	Capital increase - private placing	Cash	n.a.	126 755,04
) -			BE	n.a.	Acquisition 100%	Rumour			n.a.	n.a.
-		Galapagos NV	BE	n.a.	Minority stake unknown %	Rumour	Private Equity		n.a.	n.a.
							Development capital			

5

FINANCIAL BIOTRANSACTIONS IN ITALY FOR H1 2009												
Acquiror name		or Target y name		All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR		
1 Assicurazioni Generali SpA	IT	Recordati SpA	IT	n.a.	Minority stake unknown %	Completed			n.a.	n.a.		
2 AXA Private Equity SA Tozzi Industrie Srl	FR IT	Tre & Partners SpA	IT	n.a.	Joint venture 100%	Completed	Private Equity		n.a.	n.a.		
3 Bipiemme Gestioni SGR SpA	IT	Bouty Healthcare SpA	IT	666.00 *	Minority stake increased from 3.227% to 5.618%	Completed			n.a.	36 356,29		
4 Branca International SpA	IT	Bioera SpA	IT	1,984.00 *	Minority stake 8.1%	Completed		Cash	n.a.	29 582,83		
5 Cassa di Risparmio di Padova e Rovigo SpA	IT	Banca Prossima SpA	IT	n.a.	Minority stake unknown %	Rumour			n.a.	n.a.		
Fondazione Cariplo SpA	IT											
Compagnia di San Paolo SA	IT											
6 Compagnia di San Paolo SA	IT	Intesa SanPaolo SpA	IT		Minority stake increased from 7.96% to 9.89%	Announced		Cash	n.a.	27 608 963,73		
7 Employees	IT	Cell Therapeutics Europe Sede Secondaria		n.a.	Acquisition 100%	Rumour			n.a.	n.a.		
8 Fareva SA	FR	Istituto de Angeli Srl	IT	n.a.	Acquisition 100%	Announced			n.a.	n.a.		
9 Fin Posillipo SpA	IT	Life Science Capital SpA	IT	9000,00	Acquisition 80%	Completed			n.a.	9 199,85		
10 Fondamenta SGR SpA	IT	Directa Plus Srl	IT	3000,00	Minority stake 25%	Completed	Development capital Venture capital	Cash	n.a.	n.a.		
11 Fondamenta SGR SpA	IT	Directa Plus Srl	IT	n.a.	Minority stake unknown %	Rumour	Venture capital Development capital	Cash	n.a.	n.a.		
12 General Electric Company	US	Snia SpA	IT	2,165.00 *	Minority stake 6.648%	Completed		Cash	n.a.	43 208,19		
13 Gestore dei Servizi Elettrici Sp/	A IT	Erse	IT	n.a.	Minority stake 49%	Completed			n.a.	n.a.		
14 Haupt Pharma AG	DE	Pfizer Italia Srl's pharmaceutical manufacturing plant in Latina	IT	n.a.	Acquisition 100%	Completed			n.a.	n.a.		
15 Istituto Ganassini SpA	IT	Korff cosmetics brand	IT	9,000.00 *	Acquisition 100%	Completed			n.a.	n.a.		
16 Phidea Srl	IT	Marvin Research Srl	IT	n.a.	Merger 100%	Completed			n.a.	n.a.		
17 Reply SpA	IT	Motorola Inc's Research Center in Italy	IT	n.a.	Acquisition 100%	Announced			n.a.	n.a.		
18 SICI Sgr SpA	IT	Toscana Biomarkers SpA Digitart SpA ProtEra Srl Siena Solar Nanotech Srl	IT IT IT IT	n.a.	Minority stake	Announced	Private Equity Capital increase - placing		n.a.	n.a.		
19 Sofinnova Partners	FR	EOS (Ethical Oncology Science) SpA	IT	8200,00	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.		
Quantica SGR	IT						Development capital - 1st round					
20 Vitrolife AB	SE	ATS Srl	IT	n.a.	Acquisition increased from 60% to 70%	Completed			n.a.	n.a.		
21 Volteo Energie Srl	IT	Stea Divisione Energia Solare Srl	IT	1,600.00 *	Acquisition 51%	Withdrawn		Deferred paymer	nt n.a.	n.a.		
, i i i i i i i i i i i i i i i i i i i		5						Other Cash				
22 Yorkville bhn SpA	IT	Aq Tech SpA	IT	6600,00	Acquisition 51%	Announced	Capital increase - private placing	Cash	n.a.	19 341,18		
23 -		Snia SpA	IT	1,514.00 *	Minority stake 4.648%	Completed		Cash	n.a.	43 215,15		
24 -		Bouty Healthcare SpA	IT	n.a.	Minority stake unknown %	Completed			n.a.	n.a.		
25 -		Recordati SpA	IT	n.a.	Minority stake unknown %	Completed			n.a.	n.a.		
26 -		Recordati SpA	IT	n.a.	Minority stake unknown %	Completed			n.a.	n.a.		
27 -		Pirelli Eco Technology SpA	IT	n.a.	Minority stake 49%	Announced			n.a.	n.a.		
		57 1			,							

				FINANCIAL BIOTRA	NSA	CTIONS	N SPAIN FOR H	1 2009				
			Acquiror country code	name	Target country code	All Deal values th EUR	type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR
1		Applus+ Servicios Tecnológicos SL	ES	Ambitec Laboratorio Medioambiental SA	ES	n.a.	Acquisition 100%	Completed			n.a.	n.a.
2		AstraZeneca plc	GB	CZ Veterinaria SA's manufacturing plant in Porriño	) ES	n.a.	Acquisition 100%	Rumour			n.a.	n.a.
3		Axis Participaciones Empresariales SGECR SA		ERA Biotech SL	ES	2800,00	Minority stake unknown %	Completed	Private Equity	Cash	n.a.	n.a.
		Highgrowth Partners SGECR SA	ES						Development capital			
		Uninvest SGECR SA	ES									
4		bcnHighgrowth	ES	Archivel Technologies SL	ES	10,000.00 *	Minority stake unknown %	Rumour	Venture capital Development capital	Cash	n.a.	n.a.
5		Bullnet Capital Sociedad de Capital Riesgo SA	ES	Códice Software SL	ES	n.a.	Minority stake unknown %	Completed	Development capital	Cash	n.a.	n.a.
									Private Equity			
6		Burgundy Botanical Extracts Iberia SA	FR	Cognis GmbH's botanicals extracts business in Spain	ES	n.a.	Acquisition 100%	Completed			n.a.	n.a.
7		Caja de Ahorros de Cataluña	ES	Tradebe SA	ES	14000,00	Minority stake unknown %	Completed	Development capital	Cash	n.a.	n.a.
									Private Equity			
8		Caja de Ahorros de San Sebastian y Guipuzkoa - Kutxa	ES	Zeltia SA	ES	2,616.00 *	Minority stake increased from 2.73% to 3.02%	Completed			n.a.	950 454,97
9		Corporacion J Uriach SL	ES	SaluPharma Biosimilars SA	ES	4000,00	Acquisition 100%	Completed	Venture capital	Cash	n.a.	n.a.
		Suanfarma Biotech SGECR	ES						Development capital			
		Laboratorios Alter SA	ES									
		Laboratorios Lácer	ES									
1	0	Cross Road Biotech SA SCR de Regimen Comum	ES	Green Molecular	ES	n.a.	Institutional buy-out 75%	Completed	Development capital Venture capital	Cash	n.a.	n.a.
1	1	Eurecan Alto Rendimiento	ES	Bioglane SLNE	ES	300,00	Minority stake unknown %	Completed	Development capital	Cash	n.a.	n.a.
									Venture capital			
1	2	Fami Cuatro de Inversiones SICAV SA	ES	Progenika Innovación	ES	5,000.00 *	Minority stake 5%	Completed	Venture capital Development capital	Cash	n.a.	n.a.
13	3	Fami Cuatro de Inversiones SICAV SA	ES	Progenika Biopharma SA	ES	5000,00	Minority stake 5%	Completed	Venture capital	Cash	n.a.	97 914,44
									Development capital			
14	4	Finsiècle	СН	Farmaprojects SA	ES	n.a.	Acquisition increased from 50% to 100%	Completed			n.a.	n.a.
1	5	Iberdrola SA	ES	Iberdrola SA and SUEZ Environnement SA's	ES	n.a.	Joint venture 100%	Rumour			n.a.	n.a.
		SUEZ Environnement SA	FR	nuclear plant joint venture								
1		Invercartera Capital SCR SA	ES	Applus+ Energy	ES	300,00	Joint venture 100%	Completed	Private Equity		n 2	n 2
["		Applus+ Servicios Tecnológicos SL Energia Serveis i Noves Tecnologies SA	ES ES ES	мрриоз+ спетду	ED	500,00	John venture 100%	completed	riivate equily		n.a.	n.a.

(continued p.19)



	FINANCIAL BIOTRANSACTIONS IN SPAIN FOR H1 2009												
	Acquiror name	Acquiror country code	name	Target country code	All Deal values th EUR	type	Deal status	Deal financing	Deal method of payment		Estimated Ent. value th EUR		
17		ES	MD Anderson International España	ES	4180,00	Minority stake unknown %	Completed	Venture capital	Cash	n.a.	n.a.		
10	Inveralia SL	ES	Laboratoria Alexicall CAIs 10 and indexed	50	10100.00	Association 1000/	Anneumend	Development capital					
	Kern Pharma SL	ES	Laboratorios Almirall SA's 13 undisclosed pharmaceutical products	ES	19100,00	Acquisition 100%	Announced			n.a.	n.a.		
19	Laboratorios Del Dr. Esteve SA	ES	Esteve Teijin Healthcare SL	ES	n.a.	Joint venture 100%	Completed			n.a.	n.a.		
20	Teijin Pharma Ltd Laboratorios Pérez Giménez SA	JP ES	Ata sama Cuain	гс		laint venture 1000/	Completed						
20	Atacama Labs Oy	es Fl	Atacama Spain	ES	n.a.	Joint venture 100%	Completed			n.a.	n.a.		
21	Petratherm Ltd	AU	Petratherm Ltd and Dalkia AB's joint venture	ES	n.a.	Joint venture 100%	Announced			n.a.	n.a.		
21	Dalkia AB	SE	retratilerini Etu anu Daikia Ab 5 joint venture	LJ	11.a.	Joint venture 100 /0	Announceu			11.a.	11.d.		
22	Prous Institute for Biomedical Research SA	ES	Prous Institute for Biomedical Resear SA and FDA	ES	n.a.	Joint venture 100%	Rumour			n.a.	n.a.		
			US Food and Drugs Administration's joint venture			Joint Ventare 10070	hamour			11.0.			
22	FDA US Food and Drugs Administration Robotiker-Tecnalia	US ES	Fatronik	ES		Margar	Announced						
23	Associación Centro de Investigación	ES	Inasmet	ES	n.a.	Merger	Announced			n.a.	n.a.		
	Tecnológico Cidemco Azpeitia	LJ	mashiel	LJ									
	ESI European Software Institute Tecnalia	ES	Labein Laboratorios de Ensayos e Investigaciones	FS									
	Est Europeur sonature institute rechand	25	Industriales Tecnalia	25									
24	Seed Guipúzcoa	ES	MDRenal Life Sciences	ES	300,00	Minority stake 30%	Rumour	Development capital - seed Venture capital	Cash	n.a.	n.a.		
25	Seed Guipúzcoa	ES	Nesplora Neurosciences Support Systems SL	ES	250,00	Minority stake 30%	Rumour	Development capital - seed Venture capital	Cash	n.a.	833,33		
26	Shareholders	ES	CTL TH Engineering SL	ES	n.a.	Demerger 100%	Rumour			n.a.	n.a.		
27	Shareholders		Brainco Biopharma SL	ES	8,500.00 *	Minority stake unknown %	Completed	Development capital	Cash	n.a.	n.a.		
	Venture capital investors					·		Venture capital					
28	SII Belgium	BE	Concatel SL	ES	n.a.	Acquisition 80%	Completed		Cash	n.a.	n.a.		
29	Sinclair Pharma plc	GB	Laboratorios Novo Pharma SL	ES	330,00	Acquisition increased from	Completed	New bank facilities		n.a.	676,82		
						50.05% to 100%							
	Solar Millennium AG	DE	Ibersol Electricidad Solar Ibérica SL	ES	n.a.	Acquisition 50%	Completed			n.a.	n.a.		
	Wanbury Ltd	IN	Cantabria Pharma SL	ES	n.a.	Acquisition increased from 90% to 100%	1			n.a.	n.a.		
	XesGalicia SGECR SA Private Investors Ferroli España SA Instituto Galego de Promoción Económica	ES ES ES ES	Nutra Omega Biotecnológica Oleica SL	ES	6000,00	Minority stake unknown %	·	Development capital Venture capital	Cash	n.a.	n.a.		
33	Zeltia SA	ES	Cooper Zeltia Veterinaria SA	ES	n.a.	Acquisition increased from 100% to 100%	Rumour			n.a.	n.a.		
34	Zeltia SA	ES	Zeltia Belgique SA	ES	n.a.	Acquisition increased from 100% to 100%	Rumour			n.a.	n.a.		
35	•		Noscira SA	ES	11139,00	Minority stake unknown %	Completed	Capital increase - placing	Cash	n.a.	n.a.		
36			Laboratorios Almirall SA	ES	12,294.00 *	Minority stake 1.108%	Completed			n.a.	971 286,79		
37	-		Solvay Pharmaceuticals BV's Spanish-based pharmaceuticals manufacturing factory	ES	n.a.	Acquisition 100%	Rumour			n.a.	n.a.		
38			NeoCodex SL	ES	n.a.	Acquisition 60%	Rumour			n.a.	n.a.		
39	-		NeoCodex SL	ES	n.a.	Minority stake unknown %	Rumour	Capital increase - placing	Cash	n.a.	n.a.		
40	•		Laboratorios Cifga SA	ES	n.a.	Planned IPO unknown stake % MADRID	Rumour			n.a.	n.a.		
41	•		Palau Pharma SA	ES	15,000.00 *	Minority stake unknown %	Postponed	Capital increase - placing	Cash	n.a.	n.a.		

#### FINANCIAL BIOTRANSACTIONS IN EASTERN EUROPE FOR H1 2009

	Acquiror name	Acquiro country code		Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR
1	Aberdeen Asset Management plc	GB	Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt	HU	n.a.	Minority stake unknown %	Completed			n.a.	n.a.
2	Alapis Pharma Pharmaceutical, Industrial and Commercial Company pf Pharma Chemical and Biological Products	GR ceutical,	Lamda Applied Pharmaceuticals	GR	975,00	Acquisition 100%	Announced	Capital increase - vendor placing	Shares	n.a.	n.a.
	Alapis Pharma Pharmaceutical, Industrial and Commercial Company pf Pharma Chemical and Biological Products	GR ceutical,	n.a.	GR	21500,00	Acquisition 100%	Announced	Capital increase - vendor placing	Shares	n.a.	
4	Alapis SA	GR	Medimec SA	GR	n.a.	Acquisition increased from 49.9% to 100%	Completed			n.a.	n.a.
5	Alapis SA	GR	PNG Gerolymatos SA	GR	n.a.	Acquisition increased from 100% to 100%	Completed			n.a.	n.a.
6	Alapis SA	GR	Gerolymatos Prestige Spa S Beauty Salon Cosmetics SA	GR	1,250.00 *	Acquisition 100%	Completed			n.a.	n.a.
7	Baltic Pharma Ltd	LT	Sanitas AB	LT	22 474,79	Minority stake 15.3%	Completed	Private Equity		n.a.	234 383,25
8	Barclays Global Investors UK Holdings Ltd	l GB	Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt	HU	88,122.04 *	Minority stake 5.09%	Completed			n.a.	1 493 340,58
9	Barr Laboratories Europe BV	NL	Pliva dd	HR	93 335,68	Acquisition increased from 94.426% to 100%	Rumour		Cash	n.a.	1 577 378,76
10	Citigroup Venture Capital Internationa	al GB	Sanitas Pharma	LT	30000,00	Minority stake increased from 17.1% to 37.4%	Completed	Private Equity		n.a.	n.a.
11	Diagnostic & Therapeutic Center of Athens Hygeia SA	GR	Magnetic Health Diagnostic Imaging SA	GR	1680,00	Acquisition increased from 20% to 100%	Completed			n.a.	2100,00
12	Eesti Arengufond	EE	Goliath Wind OÜ	EE	249,08	Minority stake 21.37%	Completed	Development capital Venture capital	Cash	n.a.	1 165,57
13	Euromedic International Holdings BV	NL	HistoCyt sro	CZ	1,426.32 *	Acquisition 100%	Completed			n.a.	1 426,32
	Fortex Nutraceuticals ood	BG	Lavena AD	BG	230.08 *	Minority stake increased from 1% to 16%	Completed			n.a.	1 656,08
	Koncernas Achemos Grupe UAB	LT	Klaipedos Juru Kroviniu Kompanija AB	LT	354,21	Acquisition increased from 92.774% to 93.516%	Completed		Cash	n.a.	48 374,88
	NASDAQ OMX Tallinn AS NASDAQ OMX Riga AS NASDAQ OMX Vilnius AB Mr Ivars Bergmanis	EE LV LT	Emerging Nordic Research AS	EE	n.a.	Joint venture 100%	Completed			n.a.	n.a.

(continued p.20)



To subscribe, please call Biotech Finances Customer Service et + 33 478 24 35 20. Copiright © 2009 Ed Européennes de l'Innovation. Reporoductions is stricty prohibited. Visit our website at www.biotech-finances.xcom

	FINANCIAL BIOTRANSACTIONS IN EASTERN EUROPE FOR H1 2009													
Acquiror name	Acquirc country code	orTarget / name	Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment	Ent. value th EUR	Estimated Ent. value th EUR				
17 PowerDrive OÜ	EE	Goliath Wind OÜ	EE	249,08	Minority stake 21.37%	Completed		Cash	n.a.	1 165,57				
18 Recordati SpA	IT	Herbacos-Bofarma SRO	CZ	20.000.00 *	Acquisition 100%	Completed		Debt assume	d 20000.00	0 18 844,36				
19 Shareholders		Unipharm AD	BG	n.a.	Acquisition 50%	Completed	Capital increase - private placing	Cash	n.a.	n.a.				
20 Sopharma AD	BG	Medica AD	BG	890.76 *	Acquisition increased from 90% to 100%	Rumour	1 1 5	Cash	n.a.	9 631,71				
21 Sopharma AD	BG	Unipharm AD	BG	n.a.	Acquisition unknown stake %	Rumour			n.a.	n.a.				
22 Sopharma AD	BG	Bulgarska Roza Sevtopolis AD	BG	2,136.91 *	Acquisition increased from 49.06% to 100%	Rumour		Cash	n.a.	5 130,21				
23 SSL International plc	GB	Gainbridge Investments (Cyprus) Ltd	CY	20600,00	Acquisition 100%	Announced		Cash	n.a.	n.a.				
24 Verbund-Austrian Renewable Power GmbH	AT	Wind farm on Black Sea coast, Bulgaria	BG	n.a.	Acquisition 100%	Completed			n.a.	n.a.				
25 VioSolar Inc	GR	Energiaki EPE	GR	n.a.	Acquisition 85%	Completed			n.a.	n.a.				
26 Y Logimed SA	GR	Magnetic Health Diagnostic Imaging SA	GR	1050,00	Acquisition 70%	Completed			n.a.	1500,00				
27 Zaklady Azotowe Anwil SA	PL	Spolana AS	CZ	1 641,93	Acquisition increased from 95.7% to 100%	Completed		Cash	n.a.	66 356,88				
28 -		Sanitas AB	LT	4,394.12 *	Minority stake 5.478%	Completed			n.a.	167 703,19				
29 -		PLIVA - Lachema AS	CZ	n.a.	Acquisition unknown stake %	Rumour			n.a.	n.a.				
										/				

			FINAN		L BIOTR	ANSACTIONS IN ISRAE	L FOR H1 20	009			
	name	Acquiro country code		Target country code	All Deal values th EUR	Deal type	Deal status	Deal financing	Deal method of payment		Estimated Ent. value th EUR
1 /		IL	Medical Compression Systems (DBN) Ltd	IL	1,250.80 *	Minority stake 26%	Rumour	Capital increase - private placing	Cash	n.a.	5 003,71
2 /	Aeronautics Defense Systems Ltd	IL	Motorola Israel Ltd's Government Electronics Department	IL	15 100,91	Acquisition 100%	Announced			n.a.	n.a.
3 /	Ashkelon Technological Industries	IL	Novaremed Ltd	IL	429,51	Minority stake 35%	Completed	Venture capital Development capital	Cash	n.a.	n.a.
		IL	RX DrugOn	IL	505,30	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
6 [ [	Docor International Management Ltd Bridge Investment Fund LP Challenge Partners	US IL US IL IL	Teva Pharmaceutical Industries Ltd EarlySense Ltd	IL IL	1,574,543.94 * 1,594.67 *	Minority stake 5.364% Minority stake unknown %	Completed Completed	Capital increase - convertible loan notes Venture capital Development capital	Cash	n.a. n.a.	34 789 251,54 n.a.
7 E		IL	InSightec Ltd	IL	11,118.83 *	Institutional buy-out increased stake to 56.5%	Completed	Private Equity Development capital	Cash	n.a.	n.a.
8 E	Elbit Systems Ltd	IL	Kinetics Ltd	IL	88,064.76 *	Acquisition increased from 51% to 100%	Completed		Cash Earn-out	n.a.	179 724,01
	Erech Municipal Taxes and Real Estate Mangement	IL	Pancrea-Tech Ltd	IL	90,23	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
[ ( /	Dr Shimon Eckhouse Odin Investments Agate Medical Investments LP	IL IL IL US	Navotek Medical Ltd		7,254.21 *	Minority stake unknown %	Completed	Development capital Venture capital	Cash	n.a.	n.a.
ć	Hadasit Medical Research Services and Development Ltd nstitutional Investors	IL	Hadasit Bio-Holdings Ltd	IL	3 248,37	Minority stake 48.908%	Pending - awaiting shareholder approva	Capital increase - private placing	Cash	n.a.	3 130,31
12	Haifa Economic Corporation Ltd	IL	Quammy Infocall Spacemute	IL IL IL	721,86	Minority stake	Completed	Development capital Venture capital	Cash	n.a.	n.a.
9	nvestors Shareholders		BioLineRx Ltd		9,023.24 *	Minority stake 26.075%	Completed	Capital increase - rights issue Capital increase	Cash	n.a.	21 204,72
		US	MagneGas Israel Ltd		n.a.	Minority stake 20%	Completed			n.a.	n.a.
16 I I	Meitav Capital Mr Ralph Hahn	US IL IL US	Ventor Technologies Ltd Kamada Ltd		253 535,91 6,287.21 *	Acquisition unknown remaining stake % Minority stake 19.902%	Completed	Capital increase - private placing	Cash	n.a. n.a.	n.a. 35 083,21
(	Dfer Hi Tech Ltd Galam Ltd	IL IL IL MX	Enzymotec Ltd	IL	8 626,26	Minority stake unknown %	Completed	Development capital - 2nd round Private Equity Corporate venturing	Cash	n.a.	n.a.
		IL IL	KAHR Medical Ltd	IL	377,85	Minority stake unknown %	Completed	Development capital Corporate venturing Venture capital	Cash	n.a.	n.a.
19 F	Pittsburgh Life Sciences Greenhouse	US	Flexicath Ltd	IL	n.a.	Minority stake unknown %	Completed	Venture capital Development capital	Cash	n.a.	n.a.
(		FR BE	Hacktics Ltd	IL	2200,00	Minority stake unknown %	Completed	Venture capital Corporate venturing Development capital	Cash	n.a.	n.a.
21 1	TopSpin Medical (Israel) Inc.	IL	Kiryat Anavim Silicone Technologies Ltd		739,91	Acquisition 89%	Completed			n.a.	n.a.
	Undisclosed bidder		Evogene Ltd		2,526.51 *	Minority stake 3.437%	Completed			n.a.	53 321,18
E (	Evergreen Venture Partners Ltd Dfer Hi Tech Ltd Aurum Ventures MKI Ltd	IL IL IL US	CorAssist Cardiovascular Ltd	IL	4 094,32	Minority stake unknown %	Completed	Venture capital Development capital	Cash	n.a.	n.a.
24 -			Exalenz BioScience Ltd	IL	3 988,27	Minority stake 0.433%	Completed	Capital increase - rights issue	Cash	n.a.	915 642,67
25 -			Rosetta Genomics Ltd	IL	n.a.	Minority stake unknown %	Rumour	Capital increase	Cash		n.a.
26 -			Teva Pharmaceutical Industries Ltd	IL	34 433,63	Minority stake 0.136%	Rumour			n.a.	30 265 181,43
27 -			D-Medical Industries Ltd		328,45	Minority stake 1.917%	Completed	Capital increase	Cash		n.a.
28 -			Bio-Light Israel Life Sciences Investments Ltd		1 335,44	Minority stake 14.468%	Completed	Capital increase	Cash	n.a.	2 345,21
29 - 30 -			Micromedic Technologies Ltd D-Pharm Ltd		1 064,74 10 286,50	Minority stake 20.178% Minority stake unknown %	Announced Completed	Capital increase - private placing Capital increase - rights issue	Cash Cash	n.a. n.a.	4 610,47 n.a.

Biotech Finances is a weekly publication of Editions Européennes de l'Innovation • Director and Editor in Chief: Jacques-Bernard Taste • E-mail : jbtaste@biotechfinances.com • Deputy Editor in Chief: Juliette Lemaignen • English Office: Wina Gunn wgunn@biotech-finances.com and Steve Gunn sgunn@biotech-finances.com • Design: www.anfetamine.fr • Publication company: Editions Européennes de l'Innovation, au capital de 8,000 €• Head Office: 72 boulevard des Brotteaux - 69006 Lyon - France • Tel. : +33 (0)478 24 35 20 • Fax: +33 (0)478 24 35 20 • Incorporated in Lyon: 480 764 398 • Commission paritaire: 0606 I 79205 • ISSN: 1298-9428 • Issue Price: 37 €• Annual subscription price / 44 issues : 1 170 €• Website: http://www.biotech-finances.com • For sales and subscriptions, call: +33 (0)478 24 35 20 • Printers: Dupli-Print - 2, rue Descartes - 95330 Domont

